Podcasts about european association

CardioNerds Dr. Joseph Kassab, Dr. Mariana Garcia-Arango, and Dr. Christopher Mason explore the technological revolution of Coronary CT Angiography (CCTA) with expert faculty Dr. Michael Gallagher. The discussion details how CCTA has evolved into a frontline diagnostic and preventive tool, moving beyond simple anatomy to incorporate physiology via CT-FFR and biology through AI-driven plaque quantification. The episode reviews landmark evidence like the SCOT-HEART and PROMISE trials, the nuances of CAD-RADS 2.0 reporting, and the emerging role of AI in monitoring treatment response and personalizing cardiovascular care. Critically, they also discuss some of the assumptions and limitations of these techniques. Stay tuned for a matching review article to be submitted to US Cardiology Review, the official Journal of CardioNerds. This episode was supported by an independent medical education grant from HeartFlow. All CardioNerds education is planned, produced, and reviewed solely by CardioNerds.  Enjoy this Circulation Paths to Discovery article to learn more about the CardioNerds mission and journey. US Cardiology Review is now the official journal of CardioNerds! Submit your manuscripts here. CardioNerds Multimodality Cardiovascular Imaging PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll Pearls Shift in Paradigm: CCTA is no longer just an anatomic test; with some key limitations, it can provide anatomy, physiology (CT-FFR), and plaque biology (AI-CPA) in a single non-invasive scan. The “Power of Zero” vs. Plaque: While a normal CCTA has a >95% negative predictive value, future MIs often arise from non-obstructive plaque that traditional stress tests might miss. CAD-RADS 2.0 Utility: The addition of plaque burden modifiers (P1–P4) is a “game changer,” allowing clinicians to identify high-risk patients who need aggressive lipid-lowering despite having only mild stenosis. CT-FFR as a Virtual Stress Test: CT-FFR uses computational fluid dynamics to simulate blood flow, potentially reducing unnecessary invasive catheterizations by approximately 61% without sacrificing safety. Seeing the Invisible: AI-based quantitative plaque analysis (QCPA) can identify “subvisual” plaque and low-attenuation (lipid-rich) components that are the primary drivers of acute coronary syndromes. Show Notes How has the role of CCTA changed compared to traditional functional testing? Historically, stress testing answered “is there ischemia today?”, which often reflects late-stage disease. CCTA identifies disease across the entire spectrum, asking “is there atherosclerosis and how much plaque is present?”. Landmark evidence: SCOT-HEART showed a 41% relative risk reduction in MI at 5 years attributed to intensified preventive therapies, and PROMISE showed CCTA was better at selecting patients who truly needed invasive angiography. Diagnostic CCTA imaging depends on the protocol, contrast timing, heart rate, heart rhythm, breathholding, scanner quality, and several patient factors (obesity, prior stents, heavy calcification, complex bypass anatomy, and motion artifact all may limit imaging). “CCTA is exceptional for the right patient, with the right scanner, and the right team.” What are the key modifiers introduced in CAD-RADS 2.0, and why do they matter? CAD-RADS 2.0 moved beyond stenosis severity to include plaque burden (P0 to P4), high-risk plaque (HRP) features, and the presence of ischemia based on CT-FFR. It serves as a clinical decision support tool: a patient with mild (25-49%) stenosis but “extensive” (P4) plaque burden is considered high risk and warrants aggressive risk factor modification. How is CT-FFR calculated, and when is it most useful in clinical practice? CT-FFR uses resting CCTA data and computational fluid dynamics to create a 3D model of coronary flow during simulated maximal hyperemia. It is often used for intermediate lesions (40–90% stenosis) to predict if they are  ischemia-producing, guiding the decision whether to proceed with invasive angiography.  The assumptions necessary for this computational modeling may not apply well to patients with microvascular dysfunction, significant myocardial scar or prior infarction, or ventricular hypertrophy. Still, data indicate that CT-FFR performs similarly to PET in predicting hemodynamically significant lesions.  CT-FFR performs well at the extremes (either clearly normal or clearly abnormal). Accuracy dips, however, in the intermediate range (~0.75-0.80), where decision-making is most critical. In this grey zone, additional factors can help guide the approach, including the amount of myocardium supplied, translesional gradient, and plaque features.   CT-FFR has not been validated in distal segments, stented segments, heavily calcified coronary arteries, or in patients with severe aortic stenosis. Caution with CT-FFR should be utilized in very calcified coronary segments.  What is AI-based quantitative plaque analysis (QCPA), and what metrics are ready for clinical use? This is potentially a paradigm shift, moving away from stenosis-centric thinking to a more disease burden and plaque biology focus. QCPA uses deep learning algorithms to automatically segment the vessel wall and quantify plaque volume in mm³. Ready for “prime time” metrics include: Total Plaque Volume (TPV), non-calcified plaque volume, and Low-Attenuation Plaque (LAP) burden. Can serial CCTA be used to monitor the effectiveness of medical therapies like statins? While not yet a routine guideline-driven practice, trials like PARADIGM and EVAPORATE show that therapies can stabilize plaque; notably, CCTA is better for monitoring than CAC scores, which can be misleading as statins often increase plaque calcification as part of the stabilization process. There are no randomized trials that serial CCTAs improve outcomes. Cost and radiation exposure will be notable limitations. Serial scan timing, scan acquisition and interpretation standardization would be key. Dr. Gallagher notes that we are moving toward a world in which plaque burden may become a “treatment biomarker,” similar to tumor burden in oncology.  References 1. Coronary Computed Tomography Angiography From Clinical Uses to Emerging Technologies: JACC State-of-the-Art Review. Abdelrahman KM, Chen MY, Dey AK, et al. Journal of the American College of Cardiology. 2020;76(10):1226-1243. doi:10.1016/j.jacc.2020.06.076. 2. Non-Invasive Imaging in Coronary Syndromes: Recommendations of the European Association of Cardiovascular Imaging and the American Society of Echocardiography, in Collaboration With the American Society of Nuclear Cardiology, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. Edvardsen T, Asch FM, Davidson B, et al. Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography. 2022;35(4):329-354. doi:10.1016/j.echo.2021.12.012. 3. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Gulati M, Levy PD, Mukherjee D, et al. Journal of the American College of Cardiology. 2021;78(22):e187-e285. doi:10.1016/j.jacc.2021.07.053. 4. Contemporary, Non-Invasive Imaging Diagnosis of Chronic Coronary Artery Disease. van der Bijl P, Gulati M, Saraste A, et al. Lancet (London, England). 2025;406(10519):2577-2587. doi:10.1016/S0140-6736(25)01586-7. 5. State of the Art: Evaluation and Medical Management of Nonobstructive Coronary Artery Disease in Patients With Chest Pain: A Scientific Statement From the American Heart Association. Slipczuk L, Blankstein R, Bucciarelli-Ducci C, et al. Circulation. 2025;152(23):e443-e466. doi:10.1161/CIR.0000000000001394. 6. Diagnostic Performance of Fractional Flow Reserve Derived From Coronary CT Angiography: The ACCURATE-CT Study. Li C, Hu Y, Jiang J, et al. JACC. Cardiovascular Interventions. 2024;17(17):1980-1992. doi:10.1016/j.jcin.2024.06.027. 7. Clinical Outcomes Based on Coronary Computed Tomography-Derived Fractional Flow Reserve and Plaque Characterization. Sato Y, Motoyama S, Miyajima K, et al. JACC. Cardiovascular Imaging. 2024;17(3):284-297. doi:10.1016/j.jcmg.2023.07.013. 8. Clinical Use of Coronary Computed Tomography Angiography-Derived Fractional Flow Reserve: Expert Consensus by an International Working Group. Tang CX, Leipsic JA, Nørgaard BL, et al. European Radiology. 2026;:10.1007/s00330-025-12313-6. doi:10.1007/s00330-025-12313-6. 9. Diagnostic accuracy of computed tomography–derived fractional flow reserve: a systematic review. Cook CM, Petraco R, Shun-Shin MJ, et al. JAMA Cardiol. 2017;2(7):803-810. Doi:10.1001/jamacardio.2017.1314 10. Diagnostic performance of noninvasive fractional flow reserve derived from coronary computed tomography angiography in suspected coronary artery disease: the NXT trial (Analysis of Coronary Blood Flow Using CT Angiography: Next Steps). Nørgaard BL, Leipsic J, Gaur S, et al. J Am Coll Cardiol. 2014;63(12):1145-1155. Doi:10.1016/j.jacc.2013.11.043 11. Comparison of coronary computed tomography angiography, fractional flow reserve, and perfusion imaging for ischemia diagnosis. Driessen RS, Danad I, Stuijfzand WJ, et al. J Am Coll Cardiol. 2019;73(2):161-173. Doi:10.1016/j.jacc.2018.10.056. 12. 1-year outcomes of FFRCT-guided care in patients with suspected coronary disease: the PLATFORM study. Douglas PS, De Bruyne B, Pontone G, et al. J Am Coll Cardiol. 2016;68(5):435-445. Doi:10.1016/j.jacc.2016.05.057. 13. Comparison of an initial risk-based testing strategy vs usual testing in stable symptomatic patients with suspected coronary artery disease: the PRECISE randomized clinical trial. Douglas PS, Nanna MG, Kelsey MD, et al; PRECISE Investigators. JAMA Cardiol. 2023;8(10):904-914. Doi:10.1001/jamacardio.2023.2595. 14. Diagnostic and clinical value of FFRCT in stable chest pain patients with extensive coronary calcification: the FACC study. Mickley H, Veien KT, Gerke O, et al. JACC Cardiovasc Imaging. 2022;15(6):1046-1058. doi:10.1016/j.jcmg.2021.12.010. 15. Low-Attenuation Noncalcified Plaque on Coronary Computed Tomography Angiography Predicts Myocardial Infarction: Results From the Multicenter SCOT-HEART Trial (Scottish Computed Tomography of the HEART). Williams MC, Kwiecinski J, Doris M, et al. Circulation. 2020;141(18):1452-1462. doi:10.1161/CIRCULATIONAHA.119.044720. 16. AI-Guided Quantitative Plaque Staging Predicts Long-Term Cardiovascular Outcomes in Patients at Risk for Atherosclerotic CVD. Nurmohamed NS, Bom MJ, Jukema RA, et al. JACC. Cardiovascular Imaging. 2024;17(3):269-280. doi:10.1016/j.jcmg.2023.05.020. 17. Interaction of AI-Enabled Quantitative Coronary Plaque Volumes on Coronary CT Angiography, FFRCT, and Clinical Outcomes: A Retrospective Analysis of the ADVANCE Registry. Dundas J, Leipsic J, Fairbairn T, et al. Circulation. Cardiovascular Imaging. 2024;17(3):e016143. doi:10.1161/CIRCIMAGING.123.016143. 18. Prognostic Value of AI-Based Quantitative Coronary CTA vs Human Reader-Based Visual Assessment: Results From the CONFIRM2 Registry. van Rosendael A, Nakanishi R, Bax JJ, et al. JACC. Cardiovascular Imaging. 2026;19(3):345-359. doi:10.1016/j.jcmg.2025.09.021.13. Pericoronary Adipose Tissue as a Marker of Cardiovascular Risk: JACC Review Topic of the Week. Tan N, Dey D, Marwick TH, Nerlekar N. Journal of the American College of Cardiology. 2023;81(9):913-923. doi:10.1016/j.jacc.2022.12.021. 19. Effect of Icosapent Ethyl on Progression of Coronary Atherosclerosis in Patients With Elevated Triglycerides on Statin Therapy: Final Results of the EVAPORATE Trial. Budoff MJ, Bhatt DL, Kinninger A, et al. European Heart Journal. 2020;41(40):3925-3932. doi:10.1093/eurheartj/ehaa652. 20. Coronary CT Angiography Evaluation With Artificial Intelligence for Individualized Medical Treatment of Atherosclerosis: A Consensus Statement From the QCI Study Group. Schulze K, Stantien AM, Williams MC, et al. Nature Reviews. Cardiology. 2026;23(2):100-115. doi:10.1038/s41569-025-01191-6.

In this episode, CardioNerds Dr. Colin Blumenthal, Dr. Kelly Arps, and Dr. Yong Hao Yeo are joined by electrophysiology expert Dr. Bradley Knight to discuss atrial fibrillation (AF) management in challenging clinical scenarios. We explore arrhythmias in patients with pre-excitation syndromes, particularly Wolff-Parkinson-White (WPW) syndrome, and strategies for rhythm control. We also discuss AF management in pregnancy, adult congenital heart disease, and patients with tachycardia-bradycardia (tach-brady) syndrome. This episode provides essential insights into nuanced decision-making for the care of patients with complex arrhythmia profiles. Audio editing by CardioNerds academy intern, Grace Qiu. Enjoy this Circulation 2022 Paths to Discovery article to learn about the CardioNerds story, mission, and values. CardioNerds Atrial Fibrillation PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! PEARLS AF in WPW is a true emergency—AV nodal blocking agents can be deadly. In patients with WPW syndrome, AF can rapidly conduct through the accessory pathway, risking ventricular fibrillation and sudden death. Avoid AV nodal blockers like beta-blockers and calcium channel blockers. Catheter ablation is the first-line rhythm control strategy in WPW. Catheter ablation carries a Class I recommendation and offers >90% success. If antiarrhythmic drugs are needed, sodium channel blockers like flecainide or propafenone are preferred in patients without structural heart disease. In pregnancy, protecting the mother is protecting the fetus. An unstable mother means an unstable fetus. Rate control is the first step in AF with rapid ventricular responses and electrical cardioversion is safe when needed. Multidisciplinary care is essential. AF in congenital heart disease is often outside the pulmonary veins. Surgical scars and chamber remodeling in ACHD patients often lead to AF from non-pulmonary vein foci. Electrogram-based mapping and targeted ablation strategies are essential to increase success rate of durable rhythm control. Tachy-brady syndrome may require pacing to unlock therapy. AF may cause atrial myopathy and sinus node dysfunction. These patients often require permanent pacing to allow safe use of rate-controlling medications like beta-blockers and to prevent syncope or chronotropic incompetence. Notes: Notes drafted by Dr. Yong Hao Yeo Why is atrial tachycardia in patients with WPW syndrome dangerous? Patients with WPW commonly present with supraventricular tachycardia (SVT) due to atrioventricular reentrant circuits, either orthodromic or antidromic. This SVT can degenerate into AF. In the absence of AV nodal as the governor between the atrium and ventricles, the accessory pathway may conduct impulses rapidly and frequently. This can lead to dangerously high ventricular rates, predisposing patients to ventricular fibrillation and sudden cardiac arrest. What are some strategies for rhythm control in patients with WPW and atrial tachycardia? Catheter ablation is the first-line therapy (Class I recommendation), with a success rate of over 90%. Ablation reduces the risk of sudden cardiac arrest, though some patients may remain prone to AF. If ablation is not feasible/ contraindicated, sodium channel blockers such as flecainide and propafenone are good options in patients without ischemia or structural heart disease (Class IIa recommendation). Amiodarone should be avoided because it has a long half-life, can accumulate in the system, and may delay definitive treatment with catheter ablation. AV nodal blocking agents like beta blockers and calcium channel blockers should be avoided, as they are less effective at controlling ventricular rate in WPW and can increase conduction over the accessory pathway. These agents can also exacerbate the risk of rapid ventricular rates during AF and worsen left ventricular function. What are some special considerations in managing AF in pregnant patients? The primary goal in managing cardiovascular disease during pregnancy is to protect the mother, as fetal outcomes depend on maternal well-being. Therefore, while caution is necessary, we should avoid undertreating pregnant patients with AF. In cases of AF with rapid ventricular response (RVR), rate control is usually the first-line strategy, with beta blockers preferred over digoxin or non-dihydropyridine calcium channel blockers. It is then reasonable to initially observe for spontaneous conversion in stable patients. Antiarrhythmic drugs (AADs) are generally avoided during the first trimester, but clinical judgment on a case-by-case basis is essential. Evidence for the safety of AADs in pregnancy is limited, often derived from their use in other conditions such as fetal SVT. Flecainide and sotalol are reasonable options for rhythm control (Class IIa recommendation). Electrical cardioversion is considered safe in pregnancy and should be utilized when indicated (Do not forget!). There is no pregnancy-specific thromboembolic risk stratification tool. CHA₂DS₂-VASc scoring and the presence of risk factors like mitral stenosis can help guide anticoagulation decisions, though the magnitude of thromboembolic risk during pregnancy remains unclear. Rate control agents are typically continued during delivery due to the increased physiologic stress of labor and delivery. Multidisciplinary care is crucial and should involve obstetrics, maternal-fetal medicine, cardiology, and electrophysiology specialists. What are some key considerations for AF management in patients with adult congenital heart disease (ACHD)? Patients with repaired congenital heart disease are at increased risk for arrhythmias due to two main factors: surgical scars that create arrhythmogenic foci and mechanical remodeling of the atria or ventricles resulting from the underlying disease. In these patients with structural heart disease, sodium channel blockers may not be ideal antiarrhythmic options. When selecting an antiarrhythmic drug, clinicians must consider the nature of structural or surgical impairments, such as right bundle branch block or prolonged QT interval. It is also essential to assess renal and hepatic function (often impaired in patients with ACHD) to ensure appropriate metabolism and clearance of antiarrhythmic medications. Electrogram-based ablation strategies (those leveraging artificial intelligence are developing!) may help identify effective ablation targets, which are often outside the pulmonary veins in patients with ACHD. These individualized approaches can improve ablation success rates in this complex patient population. What makes tachycardia-bradycardia (tach-brady) syndrome a unique challenge in arrhythmia management? Patients who present with both AF and bradycardia, especially with syncope, require a thoughtful diagnostic approach to identify the underlying rhythm disturbance. Extended cardiac monitoring, including event monitors or implantable loop recorders, can help capture intermittent arrhythmias and correlate them with symptoms. AF may lead to atrial myopathy, and since the sinus node resides within the atrium, this can result in sinus node dysfunction—a hallmark of tachy-brady syndrome. Following spontaneous conversion from AF to sinus rhythm, sinus node dysfunction may persist, leading to prolonged pauses or chronotropic incompetence. Management becomes more complex when beta-blockers are needed for AF with RVR, as they can exacerbate bradycardia. Permanent pacemaker implantation is often the next step to consider. Permanent pacemaker implantation is often considered to facilitate safe rate control in these cases. In younger patients, aggressive AF burden reduction may prevent atrial remodeling and the development of true atrial myopathy, potentially avoiding pacemaker implantation. References Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2023;149(1). doi:https://doi.org/10.1161/CIR.0000000000001193 ‌ Van IC, Rienstra M, Bunting KV, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal. 2024;45(36). doi:https://doi.org/10.1093/eurheartj/ehae176 ‌ Joglar JA, Kapa S, Saarel EV, et al. 2023 HRS expert consensus statement on the management of arrhythmias during pregnancy. Heart Rhythm. Published online May 1, 2023. doi:https://doi.org/10.1016/j.hrthm.2023.05.017 ‌ Stout KK, Daniels CJ, Aboulhosn JA, et al. 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: Executive Summary. Journal of the American College of Cardiology. 2019;73(12):1494-1563. doi:https://doi.org/10.1016/j.jacc.2018.08.1028 ‌

Good afternoon, I'm _____ with today's episode of EZ News. Tai-Ex opening The Tai-Ex opened up 79-points this morning from yesterday's close, at 41,830 on turnover of $17.7-billion N-T. The market closed higher on Thursday as the electronics sector was in focus, but the gains were capped by technical resistance ahead of the 42,000-point mark - as the main board followed a rally on Wall Street overnight, led by large-cap AI-related electronics stocks. Taipei Zoo otter arrives in New Zealand for conservation program The Taipei Zoo says one of its Asian small-clawed otters has arrived at New Zealand's Auckland Zoo to participate in an international conservation program aimed at contributing to biodiversity. According to the zoo, the otter departed for Auckland on Tuesday evening to participate in the program, which is being coordinated by the European Association of Zoos and Aquaria. The program selected the Taiwan-born otter to help conserve the Asian small-clawed otter population by contributing to genetic diversity through its transfer (搬遷) to the New Zealand zoo. The otter is currently undergoing quarantine procedures in Auckland, after which it will join the zoo's Asian small-clawed otter family. The Asian small-clawed otter is the smallest otter species and is commonly found in the wetlands, rivers, and lakes of Southeast and South Asia. It is listed as "vulnerable" on the International Union for Conservation of Nature Red List of Threatened Species. Iran's Deputy Foreign Minister says India's mediator role would be welcome Iran's Deputy Foreign Minister says he told top Indian officials that Tehran would welcome any diplomatic initiative (新措施) by New Delhi regarding the West Asia war. This comes as the Foreign Ministers of BRICS nations, which include India, Russia, China, Iran, and the UAE are meeting in New Delhi. Ishan Garg tells us more. Bolivia Clashes Erupt as Miners Protest in Capital Clashes have erupted in Bolivia's capital as police use tear gas to disperse miners trying to breach the government palace. The miners set off small dynamite charges, a tactic that's become common during this second week of nationwide unrest. The unrest challenges President Rodrigo Paz, who was sworn in late last year, marking a new era after nearly 20 years of one-party rule. Thousands of miners descended (降臨) on downtown La Paz to demand labor reforms and fuel. As the hours passed, they began chanting for the president's resignation. Blockades and marches have paralyzed the Bolivian capital in recent days. Austria Eurovision Heads into Finale The Eurovision Song Contest final lineup is set after Thursday's second semifinal. Fifteen countries competed for 10 spots in Saturday's finale, with votes from national juries and viewers worldwide deciding the outcome. Denmark, Australia, and Bulgaria are among those advancing. The U.K., France, Germany, Italy, and host Austria automatically qualify. Political tensions are clouding the pan-continental pop contest, with protests against Israel's participation and a five-country boycott. Despite challenges, Eurovision plans to expand with a spinoff (分支，番外篇) in Asia later this year. Organizers also hope Hungary will return to the contest for the first time since 2016. That was the I.C.R.T. EZ News, I'm _____. －－－－以下為 SoundOn 動態廣告－－－－ 找工作不再焦慮！ 參加YS鋼鐵人職場體驗計畫，讓你在職場脫穎而出！ 專為18-29歲青年打造的免費職涯資源： 1.職涯導師陪伴精準求職 2.60小時實戰工作坊 3.知名企業3-5天職場體驗 6/14前報名迎戰三大職場試煉，煉就鋼鐵通才：https://sofm.pse.is/94dfaj -- 左岸咖啡館乘載巴黎塞納河左岸的人文底蘊，還有每個人對法式生活的美好嚮往。 走進左岸咖啡館，點一杯深焙濃郁的曼特寧風味咖啡，用極致香醇喚醒法式浪漫的靈魂… 享受一個人的獨白時光☕ 我在左岸咖啡館

O acesso à água é um direito humano, proclamado pelas Nações Unidas desde 2010. No entanto, a água é também um bem económico, cuja propriedade e valor depende do uso que fazemos dela.Neste episódio, a economista Catarina Roseta-Palma e o humorista Manel Rosa exploram as diferenças entre a água como bem privado, bem comum e bem público puro. A propósito da gestão deste recurso, fala-se do que distingue o uso consumptivo do não consumptivo, e o que se entende por «tragédia dos comuns».A conversa navega também pelos setores principais do consumo da água, do doméstico ao agrícola e ao industrial – sabia que 70% da água captada, em Portugal e no mundo, é usada na agricultura?A dupla analisa ainda as características que conferem à água um valor particular, desde a definição do preço às características específicas deste mercado.Por fim, debatem-se questões atuais: que critérios devemos aplicar para otimizar a gestão da água? Devemos defender o interesse económico ou promover o equilíbrio dos ecossistemas?Um episódio [IN]Pertinente essencial, claro e transparente – como a água. A não perder.Referências úteisAPA «Estado das massas de água superficiais e subterrâneas», (Portal do Estado de Ambiente, 2024)  BOCCALETTI, G. «Água: uma biografia» (Ed. Desassossego, 2022)BRUNO, E. M., & JESSOE, K. «Using price elasticities of water demand to inform policy» (Annual Review of Resource Economics, 13(1), 427-441, 2021) EEA, «Ecological status of surface waters in Europe» (2025)ESTEBAN, E., & ALBIAC, J. «The problem of sustainable groundwater management: the case of La Mancha aquifers, Spain» (Hydrogeology journal, 20(5), 851-863, 2012)BiosManel RosaHumorista. Estreou-se no stand up comedy em 2019, quando tinha 15 anos. Em 2023, lançou «Mais isto do que aquilo», o seu primeiro espetáculo em nome próprio. No mesmo ano, criou «DISNARRATIVO», uma espécie de vlog no Youtube, que manteve até 2025. Juntou-se ao leque de apresentadores do Curto Circuito, um programa da SIC Radical, em 2024 Catarina Roseta PalmaProfessora associada de Economia no ISCTE-IUL, onde foi diretora da Sustentabilidade. Tem trabalhado na área do ambiente, incluindo a gestão de recursos hídricos, a energia e outros temas da sustentabilidade. Consultora para diversos organismos públicos e membro da Comissão para a Reforma da Fiscalidade Verde. Foi vice-presidente da «European Association of Environmental and Resource Economists». Tem mais de 2000 observações no «iNaturalist»

How can lives and things that are rendered invisible be crucial to identity, politics, and the future? Drawing on experimental ethnographic research in northeastern Estonia, this book offers vivid answers. The Future of Hiding: Secrecy, Infrastructure, and Ecological Memory in Estonia's Siberia (Cornell UP, 2025) analyzes the territorial dimensions of secrecy and how concealment occurs in relation to energy infrastructure and identity politics in eastern Estonia. It shows that secrets and hiding places are intrinsic to human affairs, while reconsidering the possibilities of relating ethnographically to what appears to be the extraneous. Francisco Martínez highlights how basements, garages, bunkers, holes, and cottages favor alternative forms of sociality, allowing local residents to redesign the terms of their public selves. Shadow spaces in this liminal region, at the border with Russia, are created against the institutional demand to be knowable. People engage in ordinary forms of ambivalence and refusal to negotiate a sense of loss and the consequences of a century of extractive activities. The Future of Hiding invites cross-disciplinary dialogue on topics like mining, transparency, belonging and cultural landscapes, offering insights into infrastructure's reproduction and destruction, recolonizations, and the ecological memory of a sacrificed area. Francisco Martínez is an anthropologist dealing with contemporary issues of material culture through ethnographic research. His work is known for its critical insights and experimental style. He was awarded with the Early Career Prize of the European Association of Social Anthropologists and currently works as a Ramón y Cajal Senior Research Fellow at the University of Murcia, Spain. His email address is francisco.martinez14@um.es. Yadong Li is an anthropologist-in-training. He is a PhD candidate of Socio-cultural Anthropology at Tulane University. More details about his scholarship and research interests can be found here. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

How can lives and things that are rendered invisible be crucial to identity, politics, and the future? Drawing on experimental ethnographic research in northeastern Estonia, this book offers vivid answers. The Future of Hiding: Secrecy, Infrastructure, and Ecological Memory in Estonia's Siberia (Cornell UP, 2025) analyzes the territorial dimensions of secrecy and how concealment occurs in relation to energy infrastructure and identity politics in eastern Estonia. It shows that secrets and hiding places are intrinsic to human affairs, while reconsidering the possibilities of relating ethnographically to what appears to be the extraneous. Francisco Martínez highlights how basements, garages, bunkers, holes, and cottages favor alternative forms of sociality, allowing local residents to redesign the terms of their public selves. Shadow spaces in this liminal region, at the border with Russia, are created against the institutional demand to be knowable. People engage in ordinary forms of ambivalence and refusal to negotiate a sense of loss and the consequences of a century of extractive activities. The Future of Hiding invites cross-disciplinary dialogue on topics like mining, transparency, belonging and cultural landscapes, offering insights into infrastructure's reproduction and destruction, recolonizations, and the ecological memory of a sacrificed area. Francisco Martínez is an anthropologist dealing with contemporary issues of material culture through ethnographic research. His work is known for its critical insights and experimental style. He was awarded with the Early Career Prize of the European Association of Social Anthropologists and currently works as a Ramón y Cajal Senior Research Fellow at the University of Murcia, Spain. His email address is francisco.martinez14@um.es. Yadong Li is an anthropologist-in-training. He is a PhD candidate of Socio-cultural Anthropology at Tulane University. More details about his scholarship and research interests can be found here. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/critical-theory

How can lives and things that are rendered invisible be crucial to identity, politics, and the future? Drawing on experimental ethnographic research in northeastern Estonia, this book offers vivid answers. The Future of Hiding: Secrecy, Infrastructure, and Ecological Memory in Estonia's Siberia (Cornell UP, 2025) analyzes the territorial dimensions of secrecy and how concealment occurs in relation to energy infrastructure and identity politics in eastern Estonia. It shows that secrets and hiding places are intrinsic to human affairs, while reconsidering the possibilities of relating ethnographically to what appears to be the extraneous. Francisco Martínez highlights how basements, garages, bunkers, holes, and cottages favor alternative forms of sociality, allowing local residents to redesign the terms of their public selves. Shadow spaces in this liminal region, at the border with Russia, are created against the institutional demand to be knowable. People engage in ordinary forms of ambivalence and refusal to negotiate a sense of loss and the consequences of a century of extractive activities. The Future of Hiding invites cross-disciplinary dialogue on topics like mining, transparency, belonging and cultural landscapes, offering insights into infrastructure's reproduction and destruction, recolonizations, and the ecological memory of a sacrificed area. Francisco Martínez is an anthropologist dealing with contemporary issues of material culture through ethnographic research. His work is known for its critical insights and experimental style. He was awarded with the Early Career Prize of the European Association of Social Anthropologists and currently works as a Ramón y Cajal Senior Research Fellow at the University of Murcia, Spain. His email address is francisco.martinez14@um.es. Yadong Li is an anthropologist-in-training. He is a PhD candidate of Socio-cultural Anthropology at Tulane University. More details about his scholarship and research interests can be found here. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/anthropology

How can lives and things that are rendered invisible be crucial to identity, politics, and the future? Drawing on experimental ethnographic research in northeastern Estonia, this book offers vivid answers. The Future of Hiding: Secrecy, Infrastructure, and Ecological Memory in Estonia's Siberia (Cornell UP, 2025) analyzes the territorial dimensions of secrecy and how concealment occurs in relation to energy infrastructure and identity politics in eastern Estonia. It shows that secrets and hiding places are intrinsic to human affairs, while reconsidering the possibilities of relating ethnographically to what appears to be the extraneous. Francisco Martínez highlights how basements, garages, bunkers, holes, and cottages favor alternative forms of sociality, allowing local residents to redesign the terms of their public selves. Shadow spaces in this liminal region, at the border with Russia, are created against the institutional demand to be knowable. People engage in ordinary forms of ambivalence and refusal to negotiate a sense of loss and the consequences of a century of extractive activities. The Future of Hiding invites cross-disciplinary dialogue on topics like mining, transparency, belonging and cultural landscapes, offering insights into infrastructure's reproduction and destruction, recolonizations, and the ecological memory of a sacrificed area. Francisco Martínez is an anthropologist dealing with contemporary issues of material culture through ethnographic research. His work is known for its critical insights and experimental style. He was awarded with the Early Career Prize of the European Association of Social Anthropologists and currently works as a Ramón y Cajal Senior Research Fellow at the University of Murcia, Spain. His email address is francisco.martinez14@um.es. Yadong Li is an anthropologist-in-training. He is a PhD candidate of Socio-cultural Anthropology at Tulane University. More details about his scholarship and research interests can be found here. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/sociology

How can lives and things that are rendered invisible be crucial to identity, politics, and the future? Drawing on experimental ethnographic research in northeastern Estonia, this book offers vivid answers. The Future of Hiding: Secrecy, Infrastructure, and Ecological Memory in Estonia's Siberia (Cornell UP, 2025) analyzes the territorial dimensions of secrecy and how concealment occurs in relation to energy infrastructure and identity politics in eastern Estonia. It shows that secrets and hiding places are intrinsic to human affairs, while reconsidering the possibilities of relating ethnographically to what appears to be the extraneous. Francisco Martínez highlights how basements, garages, bunkers, holes, and cottages favor alternative forms of sociality, allowing local residents to redesign the terms of their public selves. Shadow spaces in this liminal region, at the border with Russia, are created against the institutional demand to be knowable. People engage in ordinary forms of ambivalence and refusal to negotiate a sense of loss and the consequences of a century of extractive activities. The Future of Hiding invites cross-disciplinary dialogue on topics like mining, transparency, belonging and cultural landscapes, offering insights into infrastructure's reproduction and destruction, recolonizations, and the ecological memory of a sacrificed area. Francisco Martínez is an anthropologist dealing with contemporary issues of material culture through ethnographic research. His work is known for its critical insights and experimental style. He was awarded with the Early Career Prize of the European Association of Social Anthropologists and currently works as a Ramón y Cajal Senior Research Fellow at the University of Murcia, Spain. His email address is francisco.martinez14@um.es. Yadong Li is an anthropologist-in-training. He is a PhD candidate of Socio-cultural Anthropology at Tulane University. More details about his scholarship and research interests can be found here. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/eastern-european-studies

How can lives and things that are rendered invisible be crucial to identity, politics, and the future? Drawing on experimental ethnographic research in northeastern Estonia, this book offers vivid answers. The Future of Hiding: Secrecy, Infrastructure, and Ecological Memory in Estonia's Siberia (Cornell UP, 2025) analyzes the territorial dimensions of secrecy and how concealment occurs in relation to energy infrastructure and identity politics in eastern Estonia. It shows that secrets and hiding places are intrinsic to human affairs, while reconsidering the possibilities of relating ethnographically to what appears to be the extraneous. Francisco Martínez highlights how basements, garages, bunkers, holes, and cottages favor alternative forms of sociality, allowing local residents to redesign the terms of their public selves. Shadow spaces in this liminal region, at the border with Russia, are created against the institutional demand to be knowable. People engage in ordinary forms of ambivalence and refusal to negotiate a sense of loss and the consequences of a century of extractive activities. The Future of Hiding invites cross-disciplinary dialogue on topics like mining, transparency, belonging and cultural landscapes, offering insights into infrastructure's reproduction and destruction, recolonizations, and the ecological memory of a sacrificed area. Francisco Martínez is an anthropologist dealing with contemporary issues of material culture through ethnographic research. His work is known for its critical insights and experimental style. He was awarded with the Early Career Prize of the European Association of Social Anthropologists and currently works as a Ramón y Cajal Senior Research Fellow at the University of Murcia, Spain. His email address is francisco.martinez14@um.es. Yadong Li is an anthropologist-in-training. He is a PhD candidate of Socio-cultural Anthropology at Tulane University. More details about his scholarship and research interests can be found here. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/politics-and-polemics

About This Episode: What does it mean to move with intention? For Alexis Milligan, movement is everything — every breath, every blink, every shift of weight tells a story. As the Resident Movement Director at the Shaw Festival, Alexis works at the intersection of physical storytelling, design, and performance, helping actors inhabit their roles from the inside out. In this episode, Phil and Alexis dig into what movement direction actually is, how it differs from choreography, and why getting rehearsal corsets and headpieces into the room early can mean the difference between injury and artistry. But Alexis's work extends well beyond the rehearsal hall. She is the creator and director of the Groundbreaking Theatre of Medicine program — an accredited continuing professional development program through the University of Toronto that brings performing arts skills directly to physicians, surgeons, and healthcare providers. The research is unambiguous: when patients feel heard and seen by their doctors, their outcomes improve. Alexis is building the bridge between those two worlds, using theatre games, movement exercises, and the transferable skills of the performing arts to fill critical gaps in medical education. Alexis also opens up about podcasting — both as the host of Finding Creativity and as the host of the Shaw Festival's own Let's Get This Shaw on the Road podcast. She and Phil share a candid conversation about the realities of building an audience for niche arts programming, the importance of pulling back the curtain for audiences, and why Canadian theatre needs to get louder about the value it brings to communities. This episode explores: What movement direction is — and how it differs from choreography The physical challenges of period costuming and why rehearsal corsets matter from day one Emotional bleed, the actor's cool-down, and the practice of 'taking off the mask' How the Theatre of Medicine is using performing arts skills to improve patient outcomes and physician well-being The power of pulling back the curtain to build new and loyal theatre audiences And much more! Guest:

In celebration of European Conference on Antennas and Propagation 2026—marking the 20th anniversary of this flagship event, held in Dublin in April 2026—Janet spoke with two of the original founders of the European Association on Antennas and Propagation, the organization behind EuCAP: Bruno Casali and Juan Mosig.  They reflect on the origins of EuCAP, including why the first conference was hosted in France, followed by editions in the United Kingdom and Germany. The story behind EuCAP's formation is both compelling and inspiring—Bruno and Juan demonstrated remarkable determination in bringing the inaugural EuCAP 2006 in Nice to life.

Ingenion Medical, run by our guest Ed Cappabianca, is going to change the standard catheter in the UK - The Foley catheter. Urinary catheter-associated infections kill 2,100 people a year and block 1.2 million hospital bed-days. And yet, the Foley catheter - the standard of care - has barely changed in 91 years. Ingenion Medical has built what replaces it.The cymactive™ 2.0R is a CE-marked, patient-controlled urethral catheter with a patented magnetic valve that is already in clinical use across the UK and 15 international markets. It is superior to either standard Foleys or intermittent catheters, and generates revenue today. Ingenion Medical are seeking investors. Here's the Investment case:• Revenue generative, regulatory approved. CE Mark achieved Q1 2024. ISO 13485 renewed October 2025. FDA pre-sub meeting completed.• Commercial traction. Distributor agreements in over 10 countries. NHS Supply Chain at contract award stage. 15 NHS hospitals active or in pipeline.• Profitable at 1,600 patients per month (80 urologists x 20 patients). Breakeven H2 2027. £49m revenue projected 2030.• Exit precedent. Comparable urology acquisitions: Urotronic > Laborie $600m;Neotract > Teleflex $1.1b; Augmenix > Boston Scientific $600m; .• World-class advisors. Advisory board includes: Professor Chris Chapple (former European Association of Urology Secretary General) and Professor Kurt Naber, global authority on urinary tract infections.If you would like the detailed Investor Pitch Deck, go to: ingenion.approvedinvestors.co.ukSummary of PodcastKey TakeawaysThe Problem: Current catheters cause frequent, costly infections (£2k–£3.5k per cycle for the NHS) and severely limit patient mobility and quality of life.The Solution: Ingenion's cymactive catheter is a 30-day, self-voiding device with no external bag, restoring patient dignity and designed to reduce infection risk.Market Validation: The NHS created a new framework channel specifically for SimActive, signaling strong support for its innovation and cost-saving potential.The Ask: Ingenion is raising £2M (for ~10% equity) to fund commercialisation, targeting a future trade sale to a major urology firm for a potential 10x investor return.The Problem with Current CathetersUrinary Retention: A common condition caused by issues like BPH (enlarged prostate), Parkinson's, MS, and spinal cord injuries.Foley Catheter (Indwelling):The 100-year-old standard, anchored by an internal balloon.Creates a "superhighway for bacteria," causing frequent, costly infections.Full cost of ownership for the NHS is ~£800/month per patient.Intermittent Catheters (Single-Use):Used 5–8 times daily, creating significant waste and inconvenience.Account for 90% (£157.5M) of the NHS's £175M annual catheter spend.Patient Impact:Fear of infection and public voiding → social isolation.Reduced fluid intake → dehydration, which can worsen conditions like dementia.The cymactive SolutionInnovation: A 30-day, self-voiding catheter with no external tubes or bags.Mechanism:An internal, patient-controlled magnetic valve.An external magnet opens the valve; removing it allows the valve to close naturally.Infection Defense:The urethra seals over the valve's end, mimicking the body's natural defense against bacteria.Anecdotal evidence suggests reduced infections and restored function.Product Pipeline:Current: cymactive for male urinary retention (CE marked).In Development: Versions for women and for male incontinence.Market Validation & CommercialisationNHS Adoption:The NHS created a new framework channel for cymactive, as it didn't fit existing categories.Ingenion was the sole applicant and signed a 2-year contract on March 12, 2026.Ordering codes are now live for hospitals.Go-to-Market Strategy:Goal: Build awareness among clinicians and patient groups.Method: Target early adopters and use their case studies, shared by the NHS innovation team, to drive broader adoption.Rationale: A randomised control trial was unfeasible because Foley catheter users were unwilling to risk being randomised to the control group.Investment OpportunityThe Ask: £2M for ~10% equity (pre-money valuation: £18M).Exit Strategy: Trade sale to a major urology firm (e.g., Coloplast, Becton Dickinson).Rationale: Leverage a large firm's infrastructure for rapid, global scaling.Target Return: A typical venture capital return of ~10x investment.Investor Profile: High Net Worth (HNW) or Sophisticated Investors.Due Diligence: Pitch deck available at ingenion.approvedinvestors.co.ukThe Next 100 Days Podcast Co-HostsGraham ArrowsmithGraham founded Finely Fettled in 2014 to provide data from The UK High Net Worth Database to marketers targeting affluent and high-net-worth customers. He's the founder of MicroYES, a Partner for MeclabsAI, creating lead generation AI Agents & Workflows and introducing the MeclabsAI Platform. Graham also provides an Answer Engine Optimisation solution to get your website in shape to be found by LLMs.Kevin ApplebyKevin specialises in finance transformation and implementing business change. He's the COO of GrowCFO, which provides both community and CPD-accredited training designed to grow the next generation of finance leaders. You can find Kevin on LinkedIn and at kevinappleby.com

With Giulia Bruno, Hospital Limerick, Limerick - Ireland and Piotr Ponikowski, Wroclaw Medical University, Wroclaw - Poland. In this episode, Giulia Bruno is joined by Piotr Ponikowski to explore the complex interplay between valvular heart disease and heart failure. As our understanding of secondary mitral and tricuspid regurgitation evolves, new questions are emerging around prognosis, optimal timing of intervention, and the role of transcatheter therapies. Together, they discuss how to approach management in these patients, the importance of guideline-directed medical therapy, and whether treating the valve can truly improve outcomes. This conversation highlights the challenges, current evidence, and future directions shaping this rapidly evolving field. Recommended readings: 2025 ESC/EACTS Guidelines for the management of valvular heart disease: Developed by the task force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). https://doi.org/10.1093/eurheartj/ehaf194 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. https://doi.org/10.1093/eurheartj/ehad195 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. https://doi.org/10.1093/eurheartj/ehab086 Coats AJ et al. The management of secondary mitral regurgitation in patients with heart failure: a joint position statement from the HFA, EACVI, EHRA, and EAPCI of the ESC. European Heart Journal. 2021. https://doi.org/10.1093/eurheartj/ehab086 Stone GW et al. Transcatheter Mitral-Valve Repair in Patients with Heart Failure. NEJM. 2018 (COAPT). DOI: 10.1056/NEJMoa1806640 Stone GW et al. Five-Year Follow-up after Transcatheter Repair of Secondary Mitral Regurgitation. NEJM. 2023. DOI: 10.1056/NEJMoa2300213 Sorajja P et al. Transcatheter Repair for Patients with Tricuspid Regurgitation. NEJM. 2023 (TRILUMINATE Pivotal). DOI: 10.1056/NEJMoa2300525 Iliadis C et al. Acute heart failure and valvular heart disease: a scientific statement of the HFA, ACVC and EAPCI of the ESC. European Journal of Heart Failure. 2023. https://doi.org/10.1002/ejhf.70043 This 2026 HFA Cardio Talk podcast series is supported by Bayer in the form of unrestricted financial support. The discussion has not been influenced in any way by its sponsor.

In this episode, we explore the challenging landscape of disinformation in healthcare with Associate Professor Dr. Lena Frischlich from the University of Southern Denmark. Lena is co-director of the Center for Digital Democracy and an expert in media psychology and communication science. Her research focuses on the interplay between the digital realm, human cognition, and behavior—particularly how manipulative online communication like propaganda and disinformation impacts on what we believe about medicines and health.Lena shares insights from her keynote at the European Association of Hospital Pharmacists Conference in Copenhagen in 2025, where she explained what makes people susceptible to misinformation and how healthcare providers can defend against it. With a background in clinical psychology and extensive research on online manipulation, she brings a unique perspective on why even intelligent, educated people fall for false information—and what we can do about it.From understanding the psychology behind misinformation to practical strategies for combating it, this episode is essential listening for anyone working in healthcare or concerned about the spread of false medical information online.For our micro-discussion we discuss the paper “Misrepresentation of semaglutide in social media” - https://pubmed.ncbi.nlm.nih.gov/40682686/ - does it do a responsible job of presenting the risks versus the benefits…? We also discuss Bullshit. Or more specifically the paper “On the reception and detection of pseudo-profound bullshit” - https://www.cambridge.org/core/journals/judgment-and-decision-making/article/on-the-reception-and-detection-of-pseudoprofound-bullshit/0D3C87BCC238BCA38BC55E395BDC9999.  What is “Brandolini's Law…?”https://en.wikipedia.org/wiki/Brandolini%27s_law As with all of our guests, Lena shares with us her Memory Evoking Medicine, a career anthem and book. Rather uniquely, Lena hasn't actually read the book she chooses but it makes Gimmo very happy nonetheless.Prof Lena Frischlich Bio: Lena Frischlich (PhD in Psychology, University of Cologne) is an Associate Professor and Co-Director of the Centre for Digital Democracy at the University of Southern Denmark (SDU). Since 2026, she is also an external faculty member at the Complexity Science Hub in Vienna. Before coming to Denmark, she served as an interim Professor for Communication at the Ludwig-Maximilians-University in Munich (2020-21 and 2023). Between 2018 and 2023, she led the junior research group “DemoRESILdigital: Democratic resilience in times of online-propaganda, fake news, fear and hate speech” at the University of Muenster, Germany. Frischlich researches the staging and effects of manipulation-oriented political online communication, including disinformation, conspiracy myths, and extremist propaganda and aims to understand how resilience against such manipulation attempts can be fostered. In her research, she combines quantitative and qualitative methods from empirical social sciences with computational measures (such as natural language processing and machine learning). Frischlich has published over 80 academic contributions, of which over 40 have appeared in peer-reviewed scholarly journals, including leading publications such as Digital Journalism, Social Media + Society, New Media & Society, and Current Opinions in Psychology. Since 2013, Frischlich has been (co-)PI on multiple third party-funded projects addressing manipulative online content and countermeasures. In the last five years alone, she has been a co-author on more than 50 academic papers and has been invited to give more than 30 talks and keynotes to different audiences. In 2023, her research was rewarded with the Sponsorship Award of the University of Münster Society for Early Career Scholars. In 2020, she was elected to the prestigious Young Colleagues of the North-Rhine Westphalian Academy of Sciences and the Arts. Frischlich is also part of the Santa Fe Institute's global counter-balance speaker series, an applied seminar series that brings together international experts studying cyberhate, misinformation, social polarization, and counter-speech. Since 2021, Frischlich has served as spokesperson of the Media Psychological Division of the German Psychological Association. She is an associate editor at Media and Communication and Digital Journalism and has been a guest editor at Digital Journalism, Media and Communication, and Studies in Media and Communication. Currently, she co-edits a special issue on the politics of misinformation at the Journal of Elections, Public Opinions, and Parties. She is an ad-hoc reviewer for over 30 academic journals and several national and international funding organisations. In 2024, she was elected to the commission of the Centre for Advanced Internet Studies. Frischlich is a popular speaker who has provided talks to various audiences, including the Federal Bank of Germany, the European Congress of Hospital Pharmacists, and the MediaTech Festival organised by the journalistic Media City Odense. She was also an invited expert for a session on disinformation as part of the North Rhine-Westphalian Parliament's inquiry commission on the handling of the COVID-19 pandemic. Frischlich is a member of the International Panel on the information environment and the European Knowledge Hub on Radicalisation.  From Prescription to Ocean — A TEDx Talk by Jamie Hayes We're incredibly proud to share that Aural Apothecary co-host Jamie Hayes has taken to the TEDx stage with a thought-provoking talk:  Prescription to Ocean: The Hidden Impact of Medicines https://www.youtube.com/watch?v=swCLNaAG5qY Jamie explores a fascinating and urgent question: What happens to our medicines once they leave the prescription pad — and how do they impact the world beyond the patient? It's a journey that connects healthcare, the environment, and our shared responsibility for the future. You'll never think about prescribing (or taking) medicines in quite the same way again. Please take a few minutes to watch, reflect, and share — this is a conversation worth having.Please follow us on LinkedIn! Let us know what you think of the show. https://www.linkedin.com/company/auralapothecary/You can listen to the Aural Apothecary playlist here; https://open.spotify.com/playlist/3OsWj4w8sxsvuwR9zMXgn5?si=tiHXrQI7QsGtSQwPyz1KBg  You can view the Aural Apothecary Library here;   https://litalist.com/shelf/view-bookcase?publicId=KN6E3OOur website is https://www.the auralapothecary.com/ To get in touch follow us on LinkedIn, Bluesky and X @auralapothecary or email us at auralapothecarypod@gmail.com. Don't forget to rate us and comment wherever you have got this podcast from.

Podcast family, welcome to Quickie #4. This one will be fun: A. Medicine changes, and changes fast. I trained with and learned the Grannum grading placental system (grades 0-III based on ultrasound appearance). Is that still a thing? We recently found a “grade III placenta at 34 weeks” as an incidental finding. Is there specific management considerations for this? Listen in for details. B. What do we do when a patient has “two GBS results” in one pregnancy hat are discordant. Listen in for that as well!1. Jaiman S, Romero R, Pacora P, et al. Disorders of Placental Villous Maturation Are Present in One-Third of Cases With Spontaneous Preterm Labor. Journal of Perinatal Medicine. 2021. 2. European Journal of Obstetrics, Gynecology, and Reproductive Biology. 2017. Sentilhes L, Sénat MV, Ancel PY, et al. Prevention of Spontaneous Preterm Birth: Guidelines for Clinical Practice From the French College of Gynaecologists and Obstetricians (CNGOF).3. Brink LT, Roberts DJ, Wright CA, et al. Placental Pathology in Spontaneous and Iatrogenic Preterm Birth: Different Entities With Unique Pathologic Features. Placenta. 2022. 4. Chitlange SM, Hazari KT, Joshi JV, Shah RK, Mehta AC. Ultrasonographically Observed Preterm Grade III Placenta and Perinatal Outcome.International Journal of Gynaecology and Obstetrics: The Official Organ of the International Federation of Gynaecology and Obstetrics. 1990. 5. Mirza FG, Ghulmiyyah LM, Tamim H, et al. To Ignore or Not to Ignore Placental Calcifications on Prenatal Ultrasound: A Systematic Review and Meta-Analysis. The Journal of Maternal-Fetal & Neonatal Medicine : The Official Journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians. 2018. 6. Quinlan RW, Cruz AC, Buhi WC, Martin M. Changes in Placental Ultrasonic Appearance. II. Pathologic Significance of Grade III Placental Changes. American Journal of Obstetrics and Gynecology. 1982. 7. Karen M. Puopolo Group B Streptococcal Disease. https://orcid.org/0000-0002-5581-8825; Published February 25, 2026 N Engl J Med 2026;394:896-905ACOG 797

The Australian government issues formal “expectations” for data centers and AI infrastructure within the country, the European Association of Commercial Television (ACT) calls for the DMA to apply to Smart TVs, and Mexico City launches a WhatsApp chatbot for 2026 FIFA World Cup tourists. MP3 Please SUBSCRIBE HERE for free or get DTNS Live ad-free.Continue reading "Australian Govt. Issues Expectations for Data Centers – DTH"

Dalla formazione, nei primi decenni del Novecento, grazie agli insegnamenti di grandi maestri quali Attilio Cabiati, Luigi Einaudi e Benedetto Croce, alla partecipazione alla prima Guerra mondiale e alle prime esperienze concrete sul campo, tra cui si segnala la collaborazione alla Rivista bancaria dei primi anni Venti, con l’incarico di redattore capo del periodico dell’Associazione bancaria italiana, fino alla laurea con una tesi in Economia monetaria conseguita nel 1920, lo stesso anno di Piero Sraffa, grande economista e suo amico per una vita. Per arrivare alla guida della Banca Commerciale italiana che resse dal 1933 al 1972, salvandola al tempo della grande crisi seguita al crollo di Wall Street del 1929 per poi rilanciarla verso una nuova espansione con criteri manageriali di avanguardia. Stiamo parlando, cari ascoltatori, di Raffaele Mattioli un protagonista di primissimo piano della storia civile, intellettuale ed economica del nostro paese. Ne parliamo grazie alla nuova edizione di un libro, pubblicato dal Mulino dal titolo “Raffaele Mattioli, una biografia intellettuale". L’autrice, che è in linea con noi questa sera, è Francesca Pino che ha diretto l’Archivio storico di Intesa San Paolo ed è stata, tra l’altro, consigliere dell’International Council on Archives dell’Unesco e della European Association for Banking History.

The ACOG 2025 guideline specifically recommends either oral or vaginal misoprostol for cervical ripening; it does not include buccal administration among its endorsed routes. With the rising rates of both obesity and labor induction, understanding the optimal agents for induction in obese patients is crucial. In a new study released ahead of print on March 4, 2026, in the AJOG, investigators from Indianapolis released findings from a secondary analysis of the IMPROVE trial (2019, AJOG) looking at the effect of obesity on buccal vs vaginal doses of misoprostol for cervical ripening. Listen in for details.1. Haas DM, Daggy J, Flannery KM, Dorr ML, Bonsack C, Bhamidipalli SS, Pierson RC, Lathrop A, Towns R, Ngo N, Head A, Morgan S, Quinney SK. A comparison of vaginal versus buccal misoprostol for cervical ripening in women for labor induction at term (the IMPROVE trial): a triple-masked randomized controlled trial. Am J Obstet Gynecol. 2019 Sep;221(3):259.e1-259.e16. doi: 10.1016/j.ajog.2019.04.037. Epub 2019 May 7. PMID: 31075246; PMCID: PMC7692024.2. ACOG July 2025: Cervical Ripening in Pregnancy, ACOG Clinical Practice Guideline No. 93. Bynarowicz, Taylor M. et al. The impact of body mass index on misoprostol dosing for labor induction: a comparison of vaginal and buccal dosage formsAmerican Journal of Obstetrics & Gynecology, Volume 0, Issue 0: https://www.ajog.org/article/S0002-9378(26)00126-2/fulltext4. Etrusco A, Sfregola G, Zendoli F, et al. Effect of Maternal Age and Body Mass Index on Induction of Labor Using Oral Misoprostol in Late-Term Pregnancies: A Retrospective Cross-Sectional Study. Gynecologic and Obstetric Investigation. 2024. 5. Prostaglandin Versus Mechanical Dilation and the Effect of Maternal Obesity on Failure to Achieve Active Labor: A Cohort Study.6. Beckwith L, Magner K, Kritzer S, Warshak CR. The Journal of Maternal-Fetal & Neonatal Medicine : The Official Journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians. 2017.

Diese Folge auf YouTube anschauenKanal abonnieren und keine neue Folge verpassen Sponsor

Vegan Joy: Joy Is Revolutionary "As I tell my students on the first day of my animal studies class: "Drop this class. Trust me, drop this class. You do not want to know what I know. I do not want to know what I know; no one wants to know what I know." So how, then, can I talk about vegan joy? Because vegan joy is how we win."  Hear more in today's episode written by Vasile Stanescu at Substack.com/@winforanimals #vegan #plantbased #plantbasedbriefing #veganism #veganjoy #animalliberation ========================== Original post: https://substack.com/home/post/p-178356785  ================= Vasile Stanescu is an associate professor of Communication at Mercer University. He has been vegan for over 20 years and has been publishing work on effective animal liberation for over a decade. He holds a PhD in Modern Thought and Literature, with a focus on environmental rhetoric, from Stanford University. Dr. Stanescu is the co-founder and former co-senior editor of the Critical Animal Studies Book Series published by Brill/Rodopi Press, co-founder of the North American Association for Critical Animal Studies (NAACAS), fellow of the European Association for Critical Animal Studies (EACAS) and former co-organizer for the the Stanford Environmental Humanities Project. Stanescu's areas of expertise are in animal studies, food studies, media studies, and environmental communication. Dr. Stanescu has conducted research on locavorism, humane meat, lab-grown meat, the effectiveness of plant-based meat substitutes, and the ethics of the removal of invasive species ============================== FOLLOW PLANT BASED BRIEFING ON: YouTube: https://www.youtube.com/@plantbasedbriefing     Spotify: https://open.spotify.com/show/2GONW0q2EDJMzqhuwuxdCF?si=2a20c247461d4ad7 Apple Podcasts: https://podcasts.apple.com/us/podcast/plant-based-briefing/id1562925866 Your podcast app of choice: https://pod.link/1562925866 Facebook: https://www.facebook.com/PlantBasedBriefing   LinkedIn: https://www.linkedin.com/company/plant-based-briefing/   Instagram: https://www.instagram.com/plantbasedbriefing/   

Doctors Lisa and Sara talk to Consultant Endocrinologist Dr Rupinder Kochhar about patients with Type 2 Diabetes. Using hypothetical cases, we talk a little bit about diagnosis, but spend most of the time discussing the details of management in younger patients as well as how to de-escalate treatment and what the goals might be in a more frail elderly patient. Disclaimer: All educational content in this podcast was developed as part of the Circulation Health collaborative working project between Boehringer Ingelheim Limited, Greater Manchester Primary Care Provider Board and Health Innovation Manchester. Content has been created by Circulation Health Clinical Leads for educational purposes, reflecting NHS Clinical Lead and guideline-based recommendations. Boehringer Ingelheim had no input into content development. They have provided financial resources to support Podcast recordings related to this project. You can use these podcasts as part of your CPD - we don't do certificates but they still count :) Resources: NICE draft guideline - Type 2 diabetes in adults: management: https://www.nice.org.uk/guidance/gid-ng10336/documents/450 Managing Heart Failure, CKD and T2DM in Primary Care: https://pckb.org/e/managing-heart-faiure-ckd-and-t2dm-in-primary-care/ Essential steps in primary care management of older people with Type 2 diabetes: an executive summary on behalf of the European geriatric medicine society (EuGMS) and the European diabetes working party for older people (EDWPOP) collaboration: https://pmc.ncbi.nlm.nih.gov/articles/PMC10628003/ Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes: https://diabetesjournals.org/care/article/45/11/2753/147671/Management-of-Hyperglycemia-in-Type-Diabetes Diabetes UK: https://www.diabetes.org.uk/ ___ We really want to make these episodes relevant and helpful: if you have any questions or want any particular areas covered then contact us on Twitter @PCKBpodcast, or leave a comment on our quick anonymous survey here: https://pckb.org/feedback Email us at: primarycarepodcasts@gmail.com ___ This podcast has been made with the support of GP Excellence and Greater Manchester Integrated Care Board. Given that it is recorded with Greater Manchester clinicians, the information discussed may not be applicable elsewhere and it is important to consult local guidelines before making any treatment decisions.  The information presented is the personal opinion of the healthcare professional interviewed and might not be representative to all clinicians. It is based on their interpretation of current best practice and guidelines when the episode was recorded. Guidelines can change; To the best of our knowledge the information in this episode is up to date as of it's release but it is the listeners responsibility to review the information and make sure it is still up to date when they listen. Dr Lisa Adams, Dr Sara MacDermott and their interviewees are not liable for any advice, investigations, course of treatment, diagnosis or any other information, services or products listeners might pursue as a result of listening to this podcast - it is the clinicians responsibility to appraise the information given and review local and national guidelines before making treatment decisions. Reliance on information provided in this podcast is solely at the listeners risk. The podcast is designed to be used by trained healthcare professionals for education only. We do not recommend these for patients or the general public and they are not to be used as a method of diagnosis, opinion, treatment or medical advice for the general public. Do not delay seeking medical advice based on the information contained in this podcast. If you have questions regarding your health or feel you may have a medical condition then promptly seek the opinion of a trained healthcare professional.

Julius Lassalle is a leadership consultant, coach, and author based in Berlin who specializes in Embodied Leadership. After experiencing "Führungsfrust" (leadership frustration) during his 5+ years leading teams in high-pressure tech and e-commerce environments, Julius developed a revolutionary methodology that integrates psychology, neuroscience, and somatic practices. How did your experience working with leadership frustration lead you to develop Embodied Leadership? What role does somatic intelligence play in helping executives who resist traditional emotional intelligence approaches? How can coaches use body-based interventions to break through with difficult leaders? How do you identify when traditional coaching approaches aren't working and when to integrate body-based methods? What is your framework for helping leaders develop authentic emotional intelligence without triggering defensiveness Julius Lassalle Julius Lassalle is a leadership consultant, coach, and author based in Berlin who specializes in Embodied Leadership. After experiencing "Führungsfrust" (leadership frustration) during his 5+ years leading teams in high-pressure tech and e-commerce environments, Julius developed a revolutionary methodology that integrates psychology, neuroscience, and somatic practices. He holds a Psychology degree from Technical University Berlin and is a certified Professional Coach (DBVC). As co-author of "Self-Empowered Leadership: and contributor to Harvard Business Manager, Julius has established himself as a thought leader in the field. He currently serves as Chair of the Board at the European Association for Gestalt Therapy and is the founder of the Alive School of Embodied Leadership & Transformation, working with organizations ranging from 51 to 10,000+ employees. Excellent Executive Coaching Podcast If you have enjoyed this episode, subscribe to our podcast on iTunes. We would love for you to leave a review. The EEC podcasts are sponsored by MKB Excellent Executive Coaching, which helps you get from where you are to where you want to be with customized leadership and coaching development programs. MKB Excellent Executive Coaching offers leadership development programs to generate action, learning, and change that is aligned with your authentic self and values. Transform your dreams into reality and invest in yourself by scheduling a discovery session with Dr. Katrina Burrus, MCC, to reach your goals. Your host is Dr. Katrina Burrus, MCC, founder and general manager of Excellent Executive Coaching, a company that specializes in leadership development.

 In this episode of Hema Now, Catherine Glass sits down with senior leaders from the European Association for Haemophilia and Allied Disorders (EAHAD) to go behind the scenes of the EAHAD 2026 Congress. The discussion explores the vision shaping the meeting, how the scientific programme is developed, and the key advances and challenges influencing haemophilia care across Europe, offering valuable insight for clinicians and researchers alike.  Timestamps:   00:00 – Introduction  01:41 – Vision of the EAHAD 2026 Congress  03:09 – Overview of the programme  06:46 – Behind the scenes of planning a congress  09:38 – New sessions to look out for  11:03 – Their programme highlights  13:38 – How the programme is curated  15:21 – Current landscape of haemophilia care in Europe  18:09 – Major advances in the field  20:25 – Unmet needs for patients  23:31 – Real-world data and registries  25:58 – Advice to young clinicians  27:28 – Hopes for the future of haemophilia care  30:21 – Their wishes for healthcare 

Ursodiol (ursodeoxycholic acid) is a prescription bile acid medication used to dissolve cholesterol gallstones, prevent gallstones during rapid weight loss, and treat liver diseases like primary biliary cholangitis (PBC) by reducing toxic bile acids and cholesterol production. It works by changing bile composition, making it less saturated with cholesterol, and is available as oral medication. Of course, it is also the foundational medication for treatment of diagnosed Intrahepatic Cholestasis of Pregnancy (ICP). Does this medication reduce adverse perinatal outcomes? In this episode, we will review a new study from the Green Journal, which will be out in February 2026, examining the recurrence risk for ICP using data from NY. In a patient with prior history of ICP, is there any guidance on monitoring of serum bile acids in the subsequent pregnancy before symptoms develop? We will explain. PLUS we will review the data on whether Ursodiol may hold promise in recurrence prevention or in reduction of adverse outcomes once the condition is diagnosed. Listen in for details. 1. 2019: Chappell LC, Bell JL, Smith A, Linsell L, Juszczak E, Dixon PH, Chambers J, Hunter R, Dorling J, Williamson C, Thornton JG; PITCHES study group. Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial. Lancet. 2019 Sep 7;394(10201):849-860. doi: 10.1016/S0140-6736(19)31270-X. Epub 2019 Aug 1. PMID: 31378395; PMCID: PMC6739598. https://pubmed.ncbi.nlm.nih.gov/31378395/2. February 08, 2025: Rahim, Mussarat N et al. Pregnancy and the liver. The Lancet. 2021; Volume 405, Issue 10477, 498 – 513 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)02351-1/fulltext3. SMFM CS 53; 20214. Rosenberg, Henri M. MD; Sarker, Minhazur R. MD; Ramos, Gladys A. MD; Bianco, Angela MD; Ferrara, Lauren MD; DeBolt, Chelsea A. MD. Intrahepatic Cholestasis of Pregnancy Recurrence in a Subsequent Pregnancy. Obstetrics & Gynecology 147(2):p 239-241, February 2026. | DOI: 10.1097/AOG.0000000000006033 https://journals.lww.com/greenjournal/fulltext/2026/02000/intrahepatic_cholestasis_of_pregnancy_recurrence.13.aspx5. Ovadia C, Sajous J, Seed PT et al. Ursodeoxycholic acid in intrahepatic cholestasis of pregnancy: a systematic review and individual participant data meta-analysis. Lancet Gastroenterol Hepatol. 2021 Jul;6(7):547-558. doi: 10.1016/S2468-1253(21)00074-1. Epub 2021 Apr 27. PMID: 33915090; PMCID: PMC8192305.6. EASL Clinical Practice Guidelines on the management of liver diseases in pregnancy. European Association for the Study of the Liver; 2023

Zoos bring us much closer to wildlife, but their existence is a controversial topic. Go online and it's easy to find groups that advocate for the closure of zoos, assessing that they do more harm than good to animals.Complaints usually relate to confinement, the lack of space, unnatural environments and crowded conditions as the main problems against animal well-being. But experts working in zoos think differently. So the question boils down to: are zoos actually beneficial to animals? Do they have a role to play in conservation? And what can we learn from zoos on the impact of human beings on animals still living in the wild?In this episode, we will investigate these questions with Martin Boye, President of the European Association for Aquatic Mammals, and Kate Werner, Senior Campaign Manager at PETA UK.Join us on our journey through the events that shape the European continent and the European Union.Production: EuropodFollow us on:LinkedInInstagram Hosted on Acast. See acast.com/privacy for more information.

Peripheral artery disease has been called the ‘silent circulatory crisis'—affecting millions, limiting mobility, and quietly raising the risk of heart attack, stroke, and limb loss. For decades, treatment focused on walking programs, aspirin, and sometimes a stent or bypass. But today, the landscape is changing. From PCSK9 inhibitors that drive cholesterol to record lows, to GLP-1 agonists like semaglutide improving walking distance, to novel antithrombotic strategies that balance bleeding and clotting—PAD care is entering a new era. In this episode, we'll explore the breakthroughs, the evidence behind them, and what they mean for patients who just want to keep moving forward." Hosted by the University of Michigan Department of Vascular Surgery: - Robert Beaulieu, Program Director - Frank Davis, Assistant Professor of Surgery - Luciano Delbono, PGY-5 House Officer - Andrew Huang, PGY-4 House Officer - Carolyn Judge, PGY-2 House Officer Learning objectives:  1.  Describe the current evidence-based recommendations for multifactorial medical management of peripheral artery disease (PAD), including lipid, glycemic, and antithrombotic strategies per 2024 SVS/AHA guidelines.  2. Interpret the clinical implications of the FOURIER trial regarding the role of PCSK9 inhibition in reducing cardiovascular events in patients with atherosclerotic disease, including PAD.  3.  Evaluate the emerging role of GLP-1 receptor agonists, such as semaglutide, in improving walking performance and quality of life among patients with diabetic PAD based on findings from the STRIDE trial. Sponsor URL: https://www.goremedical.com/ References:  H. L. Gornik et al., “2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease,” JACC, vol. 83, no. 24, pp. 2497–2604, June 2024, doi: 10.1016/j.jacc.2024.02.013. L. Mazzolai et al., “2024 ESC Guidelines for the management of peripheral arterial and aortic diseases: Developed by the task force on the management of peripheral arterial and aortic diseases of the European Society of Cardiology (ESC) Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS), the European Reference Network on Rare Multisystemic Vascular Diseases (VASCERN), and the European Society of Vascular Medicine (ESVM),” Eur Heart J, vol. 45, no. 36, pp. 3538–3700, Sept. 2024, doi: 10.1093/eurheartj/ehae179. https://pubmed.ncbi.nlm.nih.gov/40169145/ M. S. Sabatine et al., “Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease,” N Engl J Med, vol. 376, no. 18, pp. 1713–1722, May 2017, doi: 10.1056/NEJMoa1615664. https://pubmed.ncbi.nlm.nih.gov/28304224/ M. P. Bonaca et al., “Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial,” Lancet, vol. 405, no. 10489, pp. 1580–1593, May 2025, doi: 10.1016/S0140-6736(25)00509-4. https://pubmed.ncbi.nlm.nih.gov/40169145/ N. E. Hubbard, D. Lim, and K. L. Erickson, “Beef tallow increases the potency of conjugated linoleic acid in the reduction of mouse mammary tumor metastasis,” J Nutr, vol. 136, no. 1, pp. 88–93, Jan. 2006, doi: 10.1093/jn/136.1.88. https://pubmed.ncbi.nlm.nih.gov/16365064/ Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listen Behind the Knife Premium: General Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-review Trauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlas Dominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkship Dominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotation Vascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-audio-review Colorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-audio-review Surgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-audio-review Cardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-audio-review Download our App: Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049 Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

Vegan Pride: Pride is a Political Act "While researching vegan demographics, I noticed something surprising: a meaningful number of people who never consume animal products—but refuse to call themselves vegan. I call them "closet vegans."  Hear more in today's episode written by Vasile Stanescu at Substack.com/@winforanimals #vegan #plantbased #plantbasedbriefing #veganism #veganstigma #veganpride ========================== Original post: https://substack.com/home/post/p-177757504  ================= Vasile Stanescu is an associate professor of Communication at Mercer University. He has been vegan for over 20 years and has been publishing work on effective animal liberation for over a decade. He holds a PhD in Modern Thought and Literature, with a focus on environmental rhetoric, from Stanford University. Dr. Stanescu is the co-founder and former co-senior editor of the Critical Animal Studies Book Series published by Brill/Rodopi Press, co-founder of the North American Association for Critical Animal Studies (NAACAS), fellow of the European Association for Critical Animal Studies (EACAS) and former co-organizer for the the Stanford Environmental Humanities Project. Stanescu's areas of expertise are in animal studies, food studies, media studies, and environmental communication. Dr. Stanescu has conducted research on locavorism, humane meat, lab-grown meat, the effectiveness of plant-based meat substitutes, and the ethics of the removal of invasive species ============================== FOLLOW PLANT BASED BRIEFING ON: YouTube: https://www.youtube.com/@plantbasedbriefing     Spotify: https://open.spotify.com/show/2GONW0q2EDJMzqhuwuxdCF?si=2a20c247461d4ad7 Apple Podcasts: https://podcasts.apple.com/us/podcast/plant-based-briefing/id1562925866 Your podcast app of choice: https://pod.link/1562925866 Facebook: https://www.facebook.com/PlantBasedBriefing   LinkedIn: https://www.linkedin.com/company/plant-based-briefing/   Instagram: https://www.instagram.com/plantbasedbriefing/     

In today's episode, we talk to Tom Bratrud about his ongoing, long-term work with city-dwellers who migrate to rural parts of Norway. This research forms the basis of Tom's forthcoming book project, which has the working title Rurality 2.0: Redefining Urban-Rural Divides in the Mountains of Norway. Tom Bratrud is Associate Professor in Social Anthropology at the University of Bergen. His research investigates social life, political dynamics, value(es), religion/worldviews, emerging technologies, environmental issues and rural-urban relations. Prior to his work in his home valley of Valdres in southern Norway, he conducted extensive ethnographic fieldwork in Vanuatu in the South-Pacific—resulting in his first monograph Fire on the Island: Fear, Hope and a Christian Revival in Vanuatu (Berghahn 2022). Tom is the co-convenor of European Association of Social Anthropology (EASA)'s Future Anthropologies Network. Just after we spoke, Tom was also awarded the inaugural Thomas Hylland Eriksen Memorial Prize, presented during the Norwegian Anthropological Association's Conference in Oslo at the end of October 2025. In explaining their decision, the jury commented that Bratrud “unites global and local perspectives and shows how social anthropological approach and methodology become a key to understanding ongoing change.” Tom Bratrud is Associate Professor of Social Anthropology at the University of Bergen. Tom Bratrud receives the Thomas Hylland Eriksen Memorial Prize. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

In today's episode, we talk to Tom Bratrud about his ongoing, long-term work with city-dwellers who migrate to rural parts of Norway. This research forms the basis of Tom's forthcoming book project, which has the working title Rurality 2.0: Redefining Urban-Rural Divides in the Mountains of Norway. Tom Bratrud is Associate Professor in Social Anthropology at the University of Bergen. His research investigates social life, political dynamics, value(es), religion/worldviews, emerging technologies, environmental issues and rural-urban relations. Prior to his work in his home valley of Valdres in southern Norway, he conducted extensive ethnographic fieldwork in Vanuatu in the South-Pacific—resulting in his first monograph Fire on the Island: Fear, Hope and a Christian Revival in Vanuatu (Berghahn 2022). Tom is the co-convenor of European Association of Social Anthropology (EASA)'s Future Anthropologies Network. Just after we spoke, Tom was also awarded the inaugural Thomas Hylland Eriksen Memorial Prize, presented during the Norwegian Anthropological Association's Conference in Oslo at the end of October 2025. In explaining their decision, the jury commented that Bratrud “unites global and local perspectives and shows how social anthropological approach and methodology become a key to understanding ongoing change.” Tom Bratrud is Associate Professor of Social Anthropology at the University of Bergen. Tom Bratrud receives the Thomas Hylland Eriksen Memorial Prize. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/anthropology

In today's episode, we talk to Tom Bratrud about his ongoing, long-term work with city-dwellers who migrate to rural parts of Norway. This research forms the basis of Tom's forthcoming book project, which has the working title Rurality 2.0: Redefining Urban-Rural Divides in the Mountains of Norway. Tom Bratrud is Associate Professor in Social Anthropology at the University of Bergen. His research investigates social life, political dynamics, value(es), religion/worldviews, emerging technologies, environmental issues and rural-urban relations. Prior to his work in his home valley of Valdres in southern Norway, he conducted extensive ethnographic fieldwork in Vanuatu in the South-Pacific—resulting in his first monograph Fire on the Island: Fear, Hope and a Christian Revival in Vanuatu (Berghahn 2022). Tom is the co-convenor of European Association of Social Anthropology (EASA)'s Future Anthropologies Network. Just after we spoke, Tom was also awarded the inaugural Thomas Hylland Eriksen Memorial Prize, presented during the Norwegian Anthropological Association's Conference in Oslo at the end of October 2025. In explaining their decision, the jury commented that Bratrud “unites global and local perspectives and shows how social anthropological approach and methodology become a key to understanding ongoing change.” Tom Bratrud is Associate Professor of Social Anthropology at the University of Bergen. Tom Bratrud receives the Thomas Hylland Eriksen Memorial Prize. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/sociology

In today's episode, we talk to Tom Bratrud about his ongoing, long-term work with city-dwellers who migrate to rural parts of Norway. This research forms the basis of Tom's forthcoming book project, which has the working title Rurality 2.0: Redefining Urban-Rural Divides in the Mountains of Norway. Tom Bratrud is Associate Professor in Social Anthropology at the University of Bergen. His research investigates social life, political dynamics, value(es), religion/worldviews, emerging technologies, environmental issues and rural-urban relations. Prior to his work in his home valley of Valdres in southern Norway, he conducted extensive ethnographic fieldwork in Vanuatu in the South-Pacific—resulting in his first monograph Fire on the Island: Fear, Hope and a Christian Revival in Vanuatu (Berghahn 2022). Tom is the co-convenor of European Association of Social Anthropology (EASA)'s Future Anthropologies Network. Just after we spoke, Tom was also awarded the inaugural Thomas Hylland Eriksen Memorial Prize, presented during the Norwegian Anthropological Association's Conference in Oslo at the end of October 2025. In explaining their decision, the jury commented that Bratrud “unites global and local perspectives and shows how social anthropological approach and methodology become a key to understanding ongoing change.” Tom Bratrud is Associate Professor of Social Anthropology at the University of Bergen. Tom Bratrud receives the Thomas Hylland Eriksen Memorial Prize. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/european-studies

In today's episode, we talk to Tom Bratrud about his ongoing, long-term work with city-dwellers who migrate to rural parts of Norway. This research forms the basis of Tom's forthcoming book project, which has the working title Rurality 2.0: Redefining Urban-Rural Divides in the Mountains of Norway. Tom Bratrud is Associate Professor in Social Anthropology at the University of Bergen. His research investigates social life, political dynamics, value(es), religion/worldviews, emerging technologies, environmental issues and rural-urban relations. Prior to his work in his home valley of Valdres in southern Norway, he conducted extensive ethnographic fieldwork in Vanuatu in the South-Pacific—resulting in his first monograph Fire on the Island: Fear, Hope and a Christian Revival in Vanuatu (Berghahn 2022). Tom is the co-convenor of European Association of Social Anthropology (EASA)'s Future Anthropologies Network. Just after we spoke, Tom was also awarded the inaugural Thomas Hylland Eriksen Memorial Prize, presented during the Norwegian Anthropological Association's Conference in Oslo at the end of October 2025. In explaining their decision, the jury commented that Bratrud “unites global and local perspectives and shows how social anthropological approach and methodology become a key to understanding ongoing change.” Tom Bratrud is Associate Professor of Social Anthropology at the University of Bergen. Tom Bratrud receives the Thomas Hylland Eriksen Memorial Prize. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this lecture, Mark Taubert, who chairs the national DNACPR policy for Wales, and is a palliative care clinician, reviews current practices. He will encourage you to consider your own end of life care advance care plan, and attempt to write down your prior wishes. He reviews recent concerns, scandals and media outputs and looks at current resuscitation policies, guidelines and resources. He also discusses, from a clinician's point of view, how the prospect of a natural, anticipated and accepted death in the near future can be a trigger to better advance care planning. Furthermore, he looks at online conspiracy theories, and poor Covid-19 clinical practice, and outlines resources such as the Welsh TalkCPR videos, that can help improve communication in an area rife with misconceptions and misunderstanding.This lecture was recorded by Mark Taubert on the 5th of November 2025 at Bernard's Inn Hall, LondonProfessor Mark Taubert is a UK hospital consultant and clinical director at Velindre University NHS Trust in Cardiff. He is Vice-President of the Brussels-based European Association for Palliative Care (EAPC), a non-governmental organisation dedicated to worldwide improvement in palliative care. His Cardiff University academic activities include advance care planning and new media in medical settings. He is the founder of TalkCPR.com and chairs the national Future Care Planning strategy group for NHS Wales. He has advised UK government on matters relating to palliative care, treatment escalation decisions, and the last years of life. Public engagement efforts include numerous BBC programmes and a Ted Talk on how we use and misuse language in healthcare settings. He also writes for international news outlets like the Washington Post, Newsweek, the Spectator and the Guardian. The transcript of the lecture is available from the Gresham College website: https://www.gresham.ac.uk/watch-now/dnr-formsGresham College has offered free public lectures for over 400 years, thanks to the generosity of our supporters. There are currently over 2,500 lectures free to access. We believe that everyone should have the opportunity to learn from some of the greatest minds. To support Gresham College's mission, please consider making a donation: https://www.gresham.ac.uk/get-involved/support-us/make-donation/donate-today Website:  https://gresham.ac.ukX: https://x.com/GreshamCollegeFacebook: https://facebook.com/greshamcollegeInstagram: https://instagram.com/greshamcollegeBluesky: https://bsky.app/profile/greshamcollege.bsky.social TikTok: https://www.tiktok.com/@greshamcollegeSupport Us: https://www.gresham.ac.uk/get-involved/support-us/make-donation/donate-todaySupport the show

The annual European Association of Corporate Treasurers survey always reveals a plethora of engrossing insights into the mindsets of the Continent's treasurers. This year's results point to a thirst for long-term funding, a new appreciation of talent management, and a surprising passiveness towards ESG.

This week on The Beat, CTSNet Editor-in-Chief Joel Dunning spoke with Liam Burns, CEO of Qaelon Medical, about turning ideas into companies. Chapters 00:00 Intro 02:26 JANS 1, Ross Procedure Consensus Statement 13:59 JANS 2, Novel Anastomotic Device 16:03 JANS 3, Tracheobronchoplasty Disorders Analysis 18:32 JANS 4, Revasc Strategies Non-Acute Myocardial 20:22 JANS 5, EACTS Core Curriculum for Cardiac Surgeon 21:51 Video 1, Giant Right Coronary Artery Aneurysm 24:01 Video 2, Bentall-de Bono Procedure 25:29 Video 3, Democratizing MI Mitral Repair 27:01 Liam Burns Interview 37:15 Upcoming Events 38:38 Closing They explored the challenges faced by innovators and emphasized the importance of having a commercial perspective. Additionally, they discussed product design, the fundraising process, and the challenges that commercial leaders face. Burns also shared valuable advice for aspiring innovators.   Joel also highlights recent JANS articles on the EACTS expert consensus statement on the Ross procedure in adult patients, a human cadaver study on a novel anastomotic device for the sandwich technique in type A aortic dissections, a comparative analysis of distinct airway disorders, revascularization strategies for non-acute myocardial ischemic syndromes, and core curriculum for the cardiac/cardiovascular surgeon.  In addition, Joel explores the surgical repair of a giant right coronary artery aneurysm with saphenous vein interpositional grafting, the Bentall-de Bono procedure, and democratizing minimally invasive mitral repair. Before closing, Joel highlights upcoming events in CT surgery.    JANS Items Mentioned  1.) EACTS Expert Consensus Statement on the Ross Procedure in Adult Patients   2.) Novel Anastomotic Device for the Sandwich Technique in Type A Aortic Dissections—A Human Cadaver Study  3.) Tracheobronchoplasty for Excessive Dynamic Airway Collapse and Tracheobronchomalacia: A Comparative Analysis of Distinct Airway Disorders  4.) Revascularisation Strategies for Non-Acute Myocardial Ischaemic Syndromes  5.) The European Association for Cardio-Thoracic Surgery—Core Curriculum for the Cardiac/Cardiovascular Surgeon  CTSNet Content Mentioned  1.) Surgical Repair of a Giant Right Coronary Artery Aneurysm With Saphenous Vein Interpositional Grafting   2.) The Bentall-de Bono Procedure: A Novel, Time-Efficient Mattress-Type Technique for Aortic Root Anastomosis   3.) Democratizing Minimally Invasive Mitral Repair  Other Items Mentioned  1.) Perfecting TAVR Removal | Skills Sharpening With Vince Gaudiani  2.) Case of the Month: The Case of a Foreign Body  3.) Resident Video Competition  4.) Career Center   5.) CTSNet Events Calendar  Disclaimer The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.

In this episode Cath was joined by Dr Kathrin Stauffer. They chatted about how the body remembers in multiple ways and how not getting what we need in childhood impacts multiple systems in our bodies (not just the nervous system). When we are on a healing journey the expression of sadness and grieving are an important part of this journey. However, it may be that we are blocked from crying by our defences. We dived into this and talked about food, body shape, body psychotherapy, the the function of comfort eating, shame and much more. Kathrin Stauffer PhD, UKCP Registered Body Psychotherapist, is the author of ‘Emotional Neglect and the Adult in Therapy: Lifelong Consequences to a Lack of Early Attunement' (W.W. Norton 2020).Kathrin was born and educated in Switzerland. Originally a research biochemist, she retrained at the Chiron Centre for Body Psychotherapy. She lives in Cambridge in the UK and works in private practice as a body and humanistic psychotherapist, EMDR practitioner, trainer and supervisor. She previously wrote ‘Anatomy & Physiology for Psychotherapists: connecting Body & Soul' (W.W. Norton 2010). Currently she is the President of the European Association for Body Psychotherapy EABP.You can contact her via her website which is www.stauffer.co.uk.If you're enjoying this podcast. Please leave a review and rate the podcast, this really helps others to find it.To sign up for the journal prompts and Nurture.Heal.Grow (on Substack) please head to www.cathcounihan.com or @cathcounihan on Instagram. Follow Cath on social media here:Instagram: @cathcounihanSubstack: Nurture.Heal.GrowFacebook: Cath Counihan Hosted on Acast. See acast.com/privacy for more information.

In this episode Cath is joined by Dr. Kathrin Stauffer for a rich and varied discussion about emotional neglect, what causes this, how we might know we have been emotionally neglected, the interplay with narcissistic family dynamics, what constitutes narcissistic traits and how narcissism and perfectionism can play out in motherhood. Kathrin Stauffer PhD, UKCP Registered Body Psychotherapist, is the author of ‘Emotional Neglect and the Adult in Therapy: Lifelong Consequences to a Lack of Early Attunement' (W.W. Norton 2020). She was born and educated in Switzerland. Originally a research biochemist, she retrained at the Chiron Centre for Body Psychotherapy. She lives in Cambridge in the UK and works in private practice as a body and humanistic psychotherapist, EMDR practitioner, trainer and supervisor. Currently she is the President of the European Association for Body Psychotherapy EABP. Kathrin's website is www.stauffer.co.uk If you wish to work with Kathrin or have a question for her, then email her direct on kathrin@stauffer.co.ukIf you're enjoying this podcast. Please leave a review and rate the podcast, this really helps others to find it.To sign up for the journal prompts and Nurture.Heal.Grow (on Substack) please head to www.cathcounihan.com or @cathcounihan on Instagram. Follow Cath on social media here:Instagram: @cathcounihanSubstack: Nurture.Heal.GrowFacebook: Cath Counihan Hosted on Acast. See acast.com/privacy for more information.

This week on The Beat, CTSNet Editor-in-Chief Joel Dunning speaks with Dr. Marc Pelletier, division chief of cardiac surgery for the Department of Surgery at Yale School of Medicine, about patient blood management. Chapters 00:00 Intro 01:45 EACTS 2025 07:19 JANS 1, HVD Management Guidelines 16:26 JANS 2, Low-Risk AVR Evidence 19:21 JANS 3, Warden Procedure Selection 20:36 JANS 4, Primary Repair of CAT 21:48 JANS 5, NEWTON-CABG Cardiolink-5 23:20 Video 1, Acute Aortic Syndrome 24:54 Video 2, Redo TVR Under Bypass 27:13 Video 3, Giant Tension Bulla 28:47 Dr. Pelletier Interview 34:25 Outro They delve into the Society of Thoracic Surgeons (STS) guidelines on patient blood management, along with key tips. They also explore preoperative optimization, provide an example, and discuss cell savers and reducing dead space during surgery. Additionally, they touch on postoperative transfusion and the importance of performing meticulous surgery.  Joel also highlights recent JANS articles on the 2025 ESC/EACTS guidelines for the management of valvular heart disease, low-risk aortic valve replacement at the crossroads of evidence, ideal age and weight for the Warden procedure in patients with partial anomalous pulmonary venous return, a systematic meta-analysis of short- and long-term outcomes of the primary repair of common arterial trunk, and an international, randomized, double-blind, placebo-controlled trial on the effect of Evolocumab on saphenous vein graft patency after coronary artery bypass surgery.  In addition, Joel explores the surgical treatment of acute aortic syndrome, a redo tricuspid valve replacement technique under right heart bypass for a previously repaired tricuspid valve, and thoracoscopic resection of a giant tension bulla. Before closing, Joel highlights upcoming events in CT surgery.    JANS Items Mentioned  1.) 2025 ESC/EACTS Guidelines for the Management of Valvular Heart Disease: Developed by the Task Force for the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)   2.) Low-Risk Aortic Valve Replacement at the Crossroads of Evidence  3.) Is There an Ideal Age or Weight for the Warden Procedure in Patients With Partial Anomalous Pulmonary Venous Return?  4.) Primary Repair of Common Arterial Trunk: A Systematic Meta-Analysis of Short- and Long-Term Outcomes  5.) Effect of Evolocumab on Saphenous Vein Graft Patency After Coronary Artery Bypass Surgery (NEWTON-CABG CardioLink-5): An International, Randomized, Double-Blind, Placebo-Controlled Trial  CTSNet Content Mentioned  1.) Surgical Treatment of Acute Aortic Syndrome   2.) Redo Tricuspid Valve Replacement Technique Under Right Heart Bypass for a Previously Repaired Tricuspid Valve   3.) Thoracoscopic Resection of a Giant Tension Bulla   Other Items Mentioned  1.) STS/SCA/AmSECT/SABM Update to the Clinical Practice Guidelines on Patient Blood Management  2.) Transcatheter vs Surgical Aortic Valve Replacement in Lower-Risk Patients: An Updated Meta-Analysis of Randomized Controlled Trials  3.) Perfecting TAVR Removal | Skills Sharpening With Vince Gaudiani  4.) Career Center   5.) CTSNet Events Calendar  Disclaimer The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.

Contrary to popular belief, peer review has only recently become an integral step in scientific publishing. Currently seen by many as a badge of honour ensuring valid, innovative and honest research, peer review seems in reality to be increasingly thankless, exploitative, and sometimes invisible. How did we get here? In this episode of Communicable, Annie Joseph and Angela Huttner are joined by two experts, Melinda Baldwin (University of Maryland, USA) and Serge Horbach (Radboud University, Netherlands), to unpack and examine the role of peer review, why it is still essential, and how it fits within the greater editorial process. The conversation covers the history of peer review, contemporary formats including open review and the use of artificial intelligence, and thoughtful discussion on how to fix and rethink peer review. This episode was edited by Kathryn Hostettler and peer reviewed by Barbora Píšová from the Czech Republic.Related podcast episodes Communicable episode 13: The Wild West of publishing today—predatory journals and how to deal with them https://share.transistor.fm/s/e3abe9af ResourcesEASE, the European Association of Science Editors https://ease.org.uk/ Peer review week https://peerreviewweek.net/ Further readingCsiszar, A. The Scientific Journal: Authorship and the Politics of Knowledge in the Nineteenth Century. The University of Chicago Press, 2018. DOI: 10.7208/chicago/9780226553375.001.0001 Entradas, Sousa, Yan, et al. (2023) Public Deliberative Workshops – Findings. POIESIS project deliverable D2.2. https://poiesis-project.eu/deliverables/.Ross-Hellauer T and Horbach SPJM. Additional experiments required: A scoping review of recent evidence on key aspects of Open Peer Review, Research Evaluation, 2024. DOI: 10.1093/reseval/rvae004Horbach SPJM and Halffman W. The changing forms and expectation of peer review. Res Integr Peer Rev 2018. DOI: 10.1186/s41073-018-0051-5Danziger S, et al. Extraneous factors in judicial decisions. Proc Natl Acad Sci USA, 2011. DOI: 10.1073/pnas.1018033108Fyfe, A., Moxham, N., McDougall-Waters, J., & Røstvik, C. M. (2022). A History of Scientific Journals: Royal Society publishing, 1665-2015. London: UCL Press.“Misconduct in Science,” 9 February 1983, NN3-443-UD-12D-1 box 78, file “RES 12 Misconduct in Science, 1983-1987,” Papers of the NIH Director, National Archives and Records Administration, College Park, MD.Baldwin M. In Referees We Trust? How Peer Review Became a Mark of Scientific Legitimacy. MIT Press (Open Access). Work in Progress.

Who truly shapes the impact of a professional speaker—the person on stage or the team guiding them behind the scenes? Reflecting on purpose, legacy and kindness, Nick Gold, MD of Speakers Corner, shares his realisation that while he and his team may not be the ones delivering the message on stage, their role in ensuring the right speaker reaches the right audience carries both privilege and responsibility. Nick explores how fun, genuine connection and challenging traditional measures of success inform his approach to business and life. By embracing uncertainty and change with intuition and curiosity, Nick demonstrates his focus on creating meaningful indelible impacts.   KEY TAKEAWAY ‘Through the business, we have an indelible impact on people's lives and that's a responsibility but also that's the purpose.'   ABOUT THE GUEST – NICK GOLD Being a dynamic entrepreneur and business leader is at the heart of everything Nick does. From founding, scaling and growing multiple successful ventures across the speaking industry, he has established a strong track record and he thrives on challenging the status quo, embracing bold ideas and driving innovation to create impactful businesses that inspire and deliver lasting value. Together with his business partner and brother Tim and his other business partner, Michael, they're building businesses which go beyond the transactional nature of booking a speaker. They believe in forming partnerships with their clients, whether they be companies or speakers, to drive meaningful event experiences and deliver tangible value, learning and return on investment.  As an entrepreneur and a speaker industry pioneer, Nick has built and scaled several successful businesses including; Speakers Corner, Speaking Office and Future Voices.  * Speakers Corner is an award winning international speaker bureau that connects organisations with world class talent.  * Speaking Office innovates speaker representation  * Future Voices is a platform designed to help speakers understand the business of speaking and how to improve their speaking through coaching, bureaux insights, positioning and promotion as well as creating a speaker community so that they can grow together.  Nick has been president of the International Association Speaker Bureaus as well as Chair of the European Association of Speaker Bureaus.  CONNECT WITH NICK https://www.linkedin.com/in/nickgold/ https://www.linkedin.com/company/speakers-corner/posts/ https://www.linkedin.com/company/future-voices-speakers/   ABOUT THE HOST - AMY ROWLINSON Amy is a purpose and fulfilment coach, author, podcast strategist and mastermind host who empowers purpose-driven leaders to boost productivity, engagement and meaning in life and work. Through transformational conversations, Amy helps individuals overcome overwhelm and live with clarity, building living legacies along the way.   WORK WITH AMY If you're interested in how purpose can help you and your business, please book a free 30 min call via https://calendly.com/amyrowlinson/call    KEEP IN TOUCH WITH AMY Sign up for the weekly Friday Focus - https://www.amyrowlinson.com/subscribe-to-weekly-newsletter    CONNECT WITH AMY https://linktr.ee/AmyRowlinson    BUY AMY'S BOOK (2025 Business Book Awards Finalist) Focus on Why* by Amy Rowlinson with George F. Kerr – https://amzn.eu/d/6W02HWu    HOSTED BY: Amy Rowlinson   DISCLAIMER The views, thoughts and opinions expressed in this podcast belong solely to the host and guest speakers. Please conduct your own due diligence.  *As an Amazon Associate, Amy earns from qualifying purchases.  

Happy September! This month for the September 2025 episode of the RCEM Learning Podcast Andy and Dave are talking about AI interpretation of ECG findings and managing acute asthma exacerbations. We are then going back to Becky and Chris rounding off the second part of their guideline on atrial fibrillation. We'll then end with New Online. If you'd like to email us, please feel free to do so here. After listening, complete a short quiz to have your time accredited for CPD at the RCEMLearning website! (02:13) New in EM - AI vs doctor in cath lab activations Accuracy of cath lab activation decisions for STEMI-equivalent and mimic ECGs: Physicians vs. AI (Queen of Hearts by PMcardio) (Shroyer et al., 2025) (18:00) Guidelines for EM - ESC Atrial Fibrillation (Part Two) ESC - 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS) (ESC, 2024) (39:03) New in EM - Management of acute asthma exacerbations As-Needed Albuterol–Budesonide in Mild Asthma (LaForce et al., 2025) Combination fixed‐dose beta agonist and steroid inhaler as required for adults or children with mild asthma (Cochrane Library, 2021) (54:00) New Online – new articles on RCEMLearning for your CPD Understanding Medical Cannabis: Mechanisms, Indications and Clinical Integration - David Tang Safe Sedation Procedures in Adults - Duncan Russell and Shobhan B Thakore Unusual Agitation in Final Year Student - Cathy Wield and Mark Horowitz

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Novartis and Monte Rosa have entered into their second molecular glue deal worth up to $5.7 billion, with Novartis putting $120 million upfront for more of the biotech's AI-discovered degraders. The myasthenia gravis market, once sparse, is now flourishing with new treatments approved and promising late-stage trial results from companies like Argenx and Regeneron. In other news, AstraZeneca has suspended its $270 million commitment in the UK, the FDA has flip-flopped on scrapping advisory committee meetings, and Sino Biological has developed a high-throughput platform for AI-driven antibody discovery. The myasthenia gravis space is heating up with targeted therapies, with several companies releasing promising late-stage trial results. Biogen is developing a pipeline for lupus, with investors showing interest in their programs. The FDA has several actions scheduled for September, including Merck's proposed subcutaneous formulation of Keytruda. Eli Lilly's obesity pill, Orforglipron, is in focus at the European Association for the Study of Diabetes meeting. In the cancer news, Merck's Keytruda challenger faces consistency problems, while other companies like Daiichi Sankyo and Biontech report positive data. Capsida reports a patient death in a gene therapy trial, while Alkermes shows promise in narcolepsy treatment. FDA is looking to streamline the development of non-opioid painkillers. Various webinars and events are upcoming in the pharma industry. Job opportunities are available at companies like Moderna, Abbvie, and Regeneron. Overall, the biopharma industry is seeing advancements and progress in various therapeutic areas.

Michael Cremo's book Forbidden Archeology, coauthored with Richard Thompson, caused shock waves in the world of science, It exposed evidence for a human presence on this planet going much further back in time than the current dominant consensus in the world of science allows.In Extreme Human Antiquity, Cremo builds on the foundation of Forbidden Archeology, introducing explosive new cases from all phases of archeological research, from the nineteenth century to the present. Drawing on his knowledge of the history and philosophy of science, he documents how evidence for extreme human antiquity has been subjected to a process of knowledge filtration, by which this evidence is ignored, forgotten, set aside, or dismissed on flimsy grounds.Evidence for extreme human antiquity includes human bones, human footprints, and human artifacts. Cremo's understanding of what counts as human includes discoveries that have previously been attributed to Neanderthals and other hominin species. Cremo presents for each case the pros and cons for taking it as evidence for extreme human antiquity and lets readers make their own decision.MICHAEL A. CREMO is an independent historian of archeology. He is a member of the World Archaeological Congress and the European Association of Archaeologists. Cremo is the principal author of the book Forbidden Archeology, a comprehensive historical survey of archaeological anomalies. Cremo examines the history of the archeology from the standpoint of alternative worldviews, particularly worldviews with foundations in ancient Indian thought. He has given invited lectures on his work at the Royal Institution in London, the anthropology department of the Russian Academy of Sciences in Moscow, the archeology department of the Ukrainian Academy of Sciences, the Indian Institute of Science in Bangalore and many other scientific institutions. He has also lectured on his work at universities throughout the world. He is a frequent guest on radio and television programs, and has a wide presence on the web. His website is www.mcremo.comBecome a supporter of this podcast: https://www.spreaker.com/podcast/earth-ancients--2790919/support.

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: kids' A1C and tech access correlation, first generic GLP-1 for weight loss approved, Metformin cuts long covid risk, Tandem Diabetes & Eversense updates, and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Accessibility to modern diabetes technology directly correlates with A1c among children with type 1 diabetes globally. Big, cross-sectional study, conducted in 81 pediatric diabetes centers in 56 countries, found that a greater extent of reimbursement for continuous glucose monitoring (CGM), insulin pumps, glucose meters, and insulin was associated with lower A1c levels. Partha S. Kar, MD, Type 1 Diabetes & Technology lead of the National Health Service England, told Medscape Medical News, “As is now being shown in countries such as UK with widespread uptake of technology, there is now population-wide shift in A1c not seen before.”   He added, “If policymakers are serious about bringing A1c at a population level to sub-7.5% - 8% levels, then without technology it would be incredibly difficult to achieve, in my experience and opinion. Leaving the median A1c of a population at above 7.5%-8% goes with complications so that's a decision regarding investment many will have to make in the near future.”   In an accompanying editorial, Elizabeth R. Seaquist, MD, professor of diabetes, endocrinology, and metabolism and co-director of the Institute for Diabetes, Obesity, and Metabolism at the University of Minnesota, Minneapolis, called it “striking” that access to technology in and of itself was associated with improved glycemic control, given that multidisciplinary team care is also needed to provide education and behavioral or psychological support.     https://www.medscape.com/viewarticle/diabetes-tech-access-linked-a1c-kids-t1d-globally-2025a1000nn6 XX A man with type 1 in Illinois has received the first FDA-approved islet-cell replacement treatment, Lantidra, and  he is now producing his own insulin. The treatment works by restoring the body's beta cells, potentially eliminating the need for insulin injections.   The FDA approved Lantidra (donislecel) in 2023. Lantidra uses donor cells and requires lifelong immunosuppressive drugs.     Lantidra is only available at University of Illinois Chicago Health. Other universities, such as the University of Pennsylvania, continue to do islet cell transplants as part of clinical trials. Early data has shown that a majority of participants in the Lantidra clinical study were able to achieve some level of insulin independence, but it's unclear whether the benefits of donislecel outweigh the treatment's safety risks. Nearly 87 percent of participants reported infection-related adverse events, and post-operation complications included liver lacerations, bruising of the liver (hepatic hematoma), and anemia. One patient died of multi-organ failure from sepsis, which Lantidra maker CellTrans stated was “probably related” to the use of either immunosuppression or study drugs.   In addition, some industry leaders have raised the question of whether it's ethical to commercialize the use of deceased donor islet cells. https://diatribe.org/diabetes-research/first-fda-approved-islet-cell-transplant-performed?utm_campaign=feed&utm_medium=social&utm_source=later   XX Patients in the U.S. now have access to the first generic GLP-1 treatment approved for weight loss as Teva has launched its copycat of Novo Nordisk's injected Saxenda (liraglutide).   The compound, which is a GLP-1 forerunner of Novo's semaglutide products Ozempic and Wegovy, has been approved by the FDA to treat adults with obesity and those who are overweight and have weight-related medical problems.     Saxenda also is endorsed for pediatric patients ages 12 through 17 who are obese and weigh at least 60 kg (132 pounds). The treatment is for both triggering and maintaining weight loss. Saxenda is not the first GLP-1 drug that is available as a generic. In June of last year, Teva also was the first company to launch a knockoff version of Novo's Victoza, which is the same compound as Saxenda but has been approved only for patients with Type 2 diabetes. Sales of the branded versions of both Victoza and Saxenda have declined significantly in recent years as demand for Novo's semaglutide and Eli Lilly's tirzepatide products have skyrocketed. In addition, marketers of compounded products have been aggressively competing for market share in the GLP-1 space. https://www.fiercepharma.com/pharma/saxenda-knockoff-teva-launches-first-generic-glp-1-obesity   XX Metformin could cut the risk of Long COVID by 64% in overweight or obese adults who started the drug within 90 days of infection. The large observational study, published in Clinical Infectious Diseases, analysed health records of over 624,000 UK adults with COVID-19 between March 2020 and July 2023. Among these, nearly 3,000 patients who began metformin treatment soon after diagnosis were tracked for a year. Compared to non-users, their likelihood of developing Long COVID, defined as persistent symptoms 90 days or more after infection, was dramatically lower. https://www.ndtv.com/health/metformin-cuts-risk-of-long-covid-by-64-why-the-diabetes-pill-is-not-for-everyone-9242332 XX Forty-four percent of people age 15 and older living with diabetes are undiagnosed, so they don't know they have it, according to data analysis published Monday in the journal The Lancet Diabetes & Endocrinology. The study looked at data from 204 countries and territories from 2000 to 2023 in a systematic review of published literature and surveys. “The majority of people with diabetes that we report on in the study have type 2 diabetes,” said Lauryn Stafford , the lead author of the study.   “We found that 56% of people with diabetes are aware that they have the condition,” said Stafford, a researcher for the Institute for Health Metrics and Evaluation. “Globally, there's a lot of variation geographically, and also by age. So, generally, higher-income countries were doing better at diagnosing people than low- and middle-income countries.” People under 35 years were much less likely to be diagnosed if they had diabetes than people in middle age or older. Just “20% of young adults with diabetes were aware of their condition,” Stafford said. https://www.cnn.com/2025/09/08/health/diabetes-undiagnosed-half-of-americans-wellness XX A team of Hong Kong scientists is developing an injectable treatment that could potentially improve blood flow in diabetes patients' feet, in the hopes that it will reduce the need for amputation by rebuilding tissue in the arteries.   They also hope to apply the treatment to peripheral artery disease or PAD, a condition caused by the build-up of fatty deposits in arteries that affect blood circulation in the feet. “Traditional treatments for people suffering from poor blood flow in their legs are stent implantation or bypass surgery, which is invasive,” said Wong, who is also the co-founder of a biotechnology company called NutrigeneAI. He said it was his dream to turn research in the academic field into actual clinical treatments. But he added that the team still needed three to four years for further research on the treatment.   https://www.scmp.com/news/hong-kong/health-environment/article/3324671/hong-kong-scientists-developing-new-blood-flow-treatment-aid-diabetes-patients XX   Tandem Diabetes announces Health Canada authorization for distribution of the Tandem t:slim mobile application for Android and iPhone users. The Tandem t:slim mobile app allows users to deliver a bolus from their compatible smartphone, and to wirelessly upload their pump data to the cloud-based Tandem Source platform.1 The app is expected to be available later this year.   The Tandem t:slim mobile app will be available for compatible smartphones in the Apple App Store and Google Play store later in 2025. Once available, Tandem will email eligible customers with instructions on how to download and use the app.  https://www.businesswire.com/news/home/20250904665715/en/Tandem-tslim-Mobile-App-Now-Authorized-by-Health-Canada-for-iPhone-and-Android-Phones   XX Some changes to how the Eversense CGM will be rolled out.. right now it's being distributed by Ascensia Diabetes Care.  Senseonics will take back commercial control of the year long implantable CGM on January 1 in the US and expanding worldwide throughout 2026. The change was a mutual decision, according to the two companies, which said they have signed a memorandum of understanding before a definitive agreement is hammered out by the end of the year. To get started, Senseonics is also set to acquire members of Ascensia's commercial staff—including its CGM president, Brian Hansen, who is slated to become Senseonics' new chief commercial officer. https://www.fiercebiotech.com/medtech/senseonics-retake-eversense-cgm-commercial-control-ascensia-diabetes-care XX Utrecht-based medical device company ViCentra has closed an $85 million Series D round of funding led by Innovation Industries, along with existing investors Partners in Equity and Invest-NL. The round also drew support from EQT Life Sciences and Health Innovations.   The recent capital injection will be used to expand ViCentra's manufacturing capabilities, support regulatory approvals, and strengthen commercial rollout across Europe.   The funds will also be used to launch the next-generation Kaleido 2 patch pump in Europe and prepare for entry into the U.S. market.   The global insulin delivery market is growing quickly due to the increasing number of diabetes cases and demand for effective and user-friendly solutions. The market for insulin pumps is projected to exceed $14 billion by 2034. Patch pumps are the fastest-growing segment, signalling a trend toward compact and wearable devices. And here's where ViCentra is positioned to meet this need, offering a user-friendly, sleek design-led alternative to traditional systems.   Kaleido: design-led insulin delivery Kaleido is the smallest and lightest insulin patch pump developed as a lifestyle product with a particular focus on usability and personalisation.   Designed to feel more like personal technology than a traditional medical device, Kaleido features premium materials, and users can select their own favourite aluminium shells from a range of ten preset colour options.   It integrates with Diabeloop's hybrid closed-loop algorithms (DBLG1 and DBLG2) and is compatible with Dexcom CGM sensors, positioning it within the next generation of automated insulin delivery systems.   “Kaleido is a true disruptor — small, discreet, featherlight, and beautifully designed. It empowers people with diabetes by offering a more personal and distinctive choice in both function and style. Built with empathy and precision, it honours those who live with diabetes every day. With this funding, we can now meet surging European demand and fast-track our entry into the U.S. market. This is a pivotal moment — for ViCentra, and for the community we serve,” said Tom Arnold, Chief Executive Officer at ViCentra.   Improving the quality of life for diabetic patients ViCentra, led by Tom Arnold, is on a mission to improve the lives of those with diabetes.   The company reported that demand for Kaleido in Germany, France, and the Netherlands has already exceeded initial expectations.   ViCentra will present updates on Kaleido at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD), taking place September 15–19, 2025, in Vienna.   The company plans to engage with clinicians, investors, and strategic partners to further its role in the evolving diabetes care landscape.   “ViCentra is redefining insulin pump therapy with a platform that truly centres the user experience – combining clinical performance with design simplicity and wearability,” commented Caaj Greebe, Partner at Innovation Industries. “At Innovation Industries, we invest in pioneering companies that blend world-class technology with clear commercial potential. ViCentra exemplifies this by delivering a next-generation system addressing the urgent need for better treatment options in diabetes care. We're proud to lead this investment round and partner with Tom and the team as they deepen and expand their presence in Europe and prepare for U.S. entry.”   https://techfundingnews.com/dutch-vicentra-secures-85m-to-bring-insulin-patch-pump-to-more-markets/ XX Luna Diabetes announces they've raised more than 23-million dollars in early venture capital to help continue clinical trials and build out its capacity. This is the company that wants to offer a night time only, tiny, temporary insulin pump – to supplement insulin pen use. According to the company, more than 80% of the improvements in blood sugar from automated insulin delivery systems occur while the user is sleeping. Luna launched a pivotal trial late last year. https://www.fiercebiotech.com/medtech/nighttime-insulin-patch-pump-maker-luna-diabetes-raises-236m   XX Following 15 days and 150 fingerpricks, they're here. The results of the “9 sensor samba“. And what a set of a results…   Well maybe that's overplaying it a little.   Let's just say that the outcome of this n=1 experiment wasn't quite what I expected. One of the established players came out much worse than expected, while a newcomer did a lot better.   Let's dig in, and take a look at the variation. https://www.diabettech.com/cgm/the-nine-sensor-samba-results-revealed/   XX Hard work and perseverance define ranch life, but one man in eastern Montana takes it to another level. At 90, he's still living independently on the ranch he built from the ground up. Even more remarkable? He's a type 1 diabetic.   Bob Delp still begins each day just like he did decades ago, waking up on his ranch near Richey, Montana.   “I always thought if I could ever get a ranch and run a hundred cows, that's what I wanted to do from the time I was a kid,” said Delp.   He made that dream real, the hard way; after coming home from the army, he taught school, hayed for seven cents a bale and saved every cent he could.     “I worked at it real hard because I always felt like it was going to be part of getting me to that ranch that I always wanted,” said Delp.   He did it all while managing type 1 diabetes, a diagnosis that came with few answers and little hope back in the 1950s.   “The doctors tell me being a type 1 diabetic for 66 years isn't supposed to happen. Back then, it was a real challenge,” added Delp.   Statistically, it's almost unheard of. Fewer than 90 people in the world have lived more than 70 years with type 1 diabetes.     Bob credits his late wife, Donna, for helping him beat the odds.   “She has been key in that I always ate on time.”   They've faced their share of storms, both in health and out on the land. Not long after moving to Richey, a heavy snowstorm nearly tore everything apart just after they'd stepped out for dinner.   “If Donna hadn't said it was time to eat, we wouldn't have made it out of there. I guess that's one time that made me happy to have diabetes. And I think that saved us,” said Delp.     Now, he still checks his blood sugar daily but trusts his hands more than high-tech insulin pumps.   “I'm not satisfied with the sensors they have today. I just don't think they're accurate.”   To many, Bob's survival is extraordinary. To him, it's luck.   “The genes are there already, I can't change that so I guess I would have to say just lots of good luck,” said Delp.     And through it all, optimism has been his compass.   “You might fumble the ball, but if you're determined to be a winner, you'll recover that fumble someday,” said Delp.   He still welds nearly every day. Not because he has to, but because it keeps him going.   “As long as I keep doing something like this, I will not be in the nursing home,” said Delp.   https://www.kfyrtv.com/2025/08/09/against-all-odds-montana-man-thrives-with-type-1-diabetes-90/ XX Today, Dexcom is building on this belief and breaking new ground with the launch of its first open call across the U.S. and Canada in search of the next diabetes advocates—giving people with all types of diabetes a once-in-a-lifetime opportunity to raise awareness and share their voice on a global scale in the company's World Diabetes Day campaign (Nov. 14) and beyond.  Who is eligible?: Anyone age 2+ living with all types of diabetes or prediabetes can be nominated by themselves or by someone who knows them. Selected candidates will embody strength, advocacy and pride in living with diabetes or prediabetes. Where and how can I nominate myself or someone I know?: Visit Dexcom.com/WorldDiabetesDay When is the deadline to submit a nomination?: Nominations are open from September 10 through September 19 at 12pm PT. What will the selected candidates experience?:   An invite to participate in a World Diabetes Day photoshoot in Los Angeles to have their unique story featured in Dexcom's World Diabetes Day campaign The ongoing opportunity to attend events, connect with community, and raise diabetes awareness around the world XX The European Association for the Study of Diabetes (EASD) 2025 Annual Meeting will feature major clinical trial results in type 2 diabetes (T2D), type 1 diabetes (T1D), obesity, several new clinical practice guidelines, and much more. The 61st annual EASD meeting will take place on September 15-19, 2025, in Vienna, Austria.   

Contributor: Alec Coston, MD Educational Pearls: Hepatic encephalopathy (HE) is defined as a disruption in brain function that results from impaired liver function or portosystemic shunting. Manifests as various neurologic and psychiatric symptoms such as confusion, inattention, and cognitive dysfunction Although ammonia levels have historically been recognized as important criteria for HE, the diagnosis is ultimately made clinically. An elevated ammonia level lacks sensitivity and specificity for HE Trends in ammonia levels do not correlate with disease improvement or resolution A 2020 study published in the American Journal of Gastroenterology evaluated 551 patients diagnosed with hepatic encephalopathy and treated with standard therapy Only 60% of patients had an elevated ammonia level, demonstrating the limitations of ammonia levels However, a normal ammonia level in a patient with concern for HE should raise suspicion for other pathology. In patients with cirrhosis presenting with neuropsychiatric symptoms, consider HE as the diagnosis after excluding other potential causes of altered mental status (i.e., Seizure, infection, intracranial hemorrhage) The primary treatment is lactulose Works by acidifying the gastrointestinal tract. Ammonia (NH₃) is converted into ammonium (NH₄⁺), which is poorly absorbed and subsequently eliminated from the body Also exerts a laxative effect, further enhancing elimination References: Haj M, Rockey DC. Ammonia Levels Do Not Guide Clinical Management of Patients With Hepatic Encephalopathy Caused by Cirrhosis. Am J Gastroenterol. 2020 May;115(5):723-728. doi: 10.14309/ajg.0000000000000343. PMID: 31658104. Lee F, Frederick RT. Hepatic Encephalopathy-A Guide to Laboratory Testing. Clin Liver Dis. 2024 May;28(2):225-236. doi: 10.1016/j.cld.2024.01.003. Epub 2024 Jan 30. PMID: 38548435. Vilstrup, Hendrik1; Amodio, Piero2; Bajaj, Jasmohan3,4; Cordoba, Juan1,5; Ferenci, Peter6; Mullen, Kevin D.7; Weissenborn, Karin8; Wong, Philip9. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study Of Liver Diseases and the European Association for the Study of the Liver. Hepatology 60(2):p 715-735, August 2014. | DOI: 10.1002/hep.27210 Weissenborn K. Hepatic Encephalopathy: Definition, Clinical Grading and Diagnostic Principles. Drugs. 2019 Feb;79(Suppl 1):5-9. doi: 10.1007/s40265-018-1018-z. PMID: 30706420; PMCID: PMC6416238. Summarized by Ashley Lyons, OMS3 | Edited by Ashley Lyons & Jorge Chalit, OMS4 Get your tickets to Tox Talks Event, Sept 11, 2025: https://emergencymedicalminute.org/events-2/ Donate: https://emergencymedicalminute.org/donate/  

Happy August! This month for the August 2025 episode of the RCEM Learning Podcast Andy returns to discuss the investigation of acute coronary syndrome in the ED. Becky and Chris begin a two part deep dive through a guideline looking at the management of atrial fibrillation. We then talk to Matt Reed about the RCEM Flagship Conference and we then end with New Online! If you'd like to email us, please feel free to do so here. After listening, complete a short quiz to have your time accredited for CPD at the RCEMLearning website! (02:28) New in EM - Ruling out ACS in the ED Acute coronary syndrome rule-out strategies in the emergency department: an observational evaluation of clinical effectiveness and current UK practice (Trainee Emergency Research Network, 2025) (19:43) Guidelines for EM - Atrial Fibrillation (European Society of Cardiology) European Society of Cardiology - 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): Developed by the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC), with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Endorsed by the European Stroke Organisation (ESO) (ESC, 2025) (47:26) Matt Reed and the Flagship Conference RCEM - Flagship Conference 2026 (58:28) New Online – new articles on RCEMLearning for your CPD Kishan Indrakumar, Thomas Moore, Mayank Nagar, Preetibah Ratenavelu, Dominique Tirian - Chemical Eye Injuries in the ED Katy Guy, Olivia Curtis-Hughes - Sports-Related Concussions in the Emergency Department Susan Elizabeth Dorrian, Sarah Jones - Disturbed or Psychiatric Patients in the ED Additional Links RCEM - SECEM Conference 2025

In this episode, Dr. Linda Chu explores a major Radiology consensus statement on optimizing CT angiography for suspected pulmonary embolism. The discussion covers advanced imaging techniques, key considerations for special populations, and standardized reporting practices to improve diagnostic clarity and patient outcomes. Optimal Approach to Performing and Reporting ComputedTomography Angiography for Suspected Acute PulmonaryEmbolism: A Clinical Consensus Statement of the ESC Working Groupon Pulmonary Circulation & Right Ventricular Function, the FleischnerSociety, the Association for Acute Cardiovascular Care (ACVC) andthe European Association of Cardiovascular Imaging (EACVI) of theESC, Endorsed by European Respiratory Society (ERS), Asian Societyof Thoracic Radiology (ASTR), European Society of Thoracic Imaging(ESTI), and Society of Thoracic Radiology (STR). Radiology 2025; 315(3):e243833.

Ghana's twentieth century was one of dramatic political, economic, and environmental change. Sparked initially by the impositions of colonial rule, these transformations had significant, if rarely uniform, repercussions for the determinants of good and bad nutrition. All across this new and uneven polity, food production, domestic reproduction, gender relations, and food cultures underwent radical and rapid change. This volatile national history was matched only by the scientific instability of nutritional medicine during these same years. Moving between the dry Northern savannah, the mineral-rich and food-secure Southern rainforest, and the youthful, ever-expanding cities, John Nott's Between Feast and Famine: Food, Health, and the History of Ghana's Long Twentieth-Century (UCL Press, 2025) is a comparative history of nutrition in Ghana since the end of the nineteenth century. At the heart of this story is an analysis of how an uneven capitalist transformation variously affected the lives of women and children. It traces the change from sporadic periods of hunger in the nineteenth and early twentieth centuries, through epidemics of childhood malnutrition during the twentieth century, and into emergent epidemics of diet-related non-communicable disease in the twenty-first century. Employing a novel, critical approach to historical epidemiology, Nott argues that detailing the co-production of science and its subjects in the past is essential for understanding and improving health in the present. John Nott is a Research Fellow in Science, Technology and Innovation Studies at the University of Edinburgh. His research interests sit primarily across the history of medicine and economic history, with a particular focus on colonial and postcolonial contexts. He also has complementary interests in medical anthropology and STS, and is currently a Research Fellow on Lukas Engelmann's ERC-funded project, "The Epidemiological Revolution: A History of Epidemiological Reasoning in the Twentieth Century." Amongst other things, he is working on a monograph detailing the economic and medical history of surveillance in Anglophone Africa. Dr. Nott is also the Principal Investigator of a collaborative British Academy-funded project, "Population Health in Practice: Towards a Comparative Historical Ethnography of the Demographic Health Survey," which explores the history and contemporary production of epidemiological and demographic data in Ghana, Tanzania, and Malawi. Dr. Nott was trained at the University of Leeds, where his PhD focused on the history of nutrition and nutritional medicine in Ghana since the end of the nineteenth century. Immediately before coming to Edinburgh, he was a fellow at the Merian Institute for Advanced Studies in Africa (MIASA) at the University of Ghana. Before this, Dr. Nott was based at Maastricht University as a Research Fellow on Anna Harris' ERC-funded project, “Making Clinical Sense: a Historical-Ethnographic Study of the Technologies Used in Medical Education. The edited collection, “Making Sense of Medicine: Material Culture and the Reproduction of Medical Knowledge,” recently won the Amsterdamska Award by the European Association for the Study of Science & Technology (EASST). You can learn more about his work here. Afua Baafi Quarshie is a Ph.D. candidate in history at the Johns Hopkins University. Her research focuses on mothering and childhood in post-independence Ghana. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

Shoot us a Text.Episode #1061: China's rare earth restrictions are causing real pain for Europe's automakers, Costco's gas game and checkout tech are stepping up, and American shoppers are oddly calm about rising tariffs—at least for now.Show Notes with links:China's tightened grip on rare earth exports is starting to squeeze Europe's auto manufacturing sector. With critical materials stuck in red tape and only a quarter of export licenses approved, major OEMs and suppliers are bracing for broader production halts in the coming weeks.CLEPA, the European Association of Automotive Suppliers, says hundreds of export license requests were submitted, but only 25% approved since April.Parts plant shutdowns are already affecting suppliers to VW, Mercedes-Benz, BMW, and Bosch.The slowdown stems from China's April decision to suspend exports of rare earths and magnets amid a trade standoff with the U.S.Delays in customs clearance and license processing are compounding the issue, say VDA (the German Automotive Industry Association) and CLEPA.China may ease restrictions for certain European semiconductor firms, but auto remains at risk.“Production delays and even production outages can no longer be ruled out,” said VDA President Hildegard Mueller.America's third-largest retailer is leaning into its members-first model. Costco is expanding hours at gas stations, testing scan-and-go checkout tech, and adding flexible payment options to stay competitive in a tightening retail race.Gas stations now open nationwide until 10 p.m., with select sites opening earlier too.CEO Rob Vachris says the goal is to drive more foot—and fuel—traffic by boosting convenience.Gas accounted for 12% of Costco's total sales in 2024, thanks to exclusive member access and competitive prices.“Scan & Pay” via smartphone is being piloted to streamline checkout, competing with Sam's Club's tech-forward edge.Costco has also teamed with Affirm for monthly payment plans as shoppers look beyond credit cards.A new survey by Modern Retail highlights that while many Americans are concerned about rising costs and tariffs, their spending behavior has yet to shift significantly.76% of surveyed consumers said they were familiar with recent tariffs; over half believe tariffs increase prices for everyday goods.Despite that concern, 40% reported no notable changes in their purchasing habits.A majority of respondents said they were either delaying planned purchases due to higher prices or had already bought items early to avoid anticipated tariff-related cost increases.Electronics and clothing were identified as the most likely categories to see reduced spending.Over half of respondents expressed optimism about their financial outlook for the next six months.Join Paul J Daly and Kyle Mountsier every morning for the Automotive State of the Union podcast as they connect the dots across car dealerships, retail trends, emerging tech like AI, and cultural shifts—bringing clarity, speed, and people-first insight to automotive leaders navigating a rapidly changing industry.Get the Daily Push Back email at https://www.asotu.com/ JOIN the conversation on LinkedIn at: https://www.linkedin.com/company/asotu/